ÕæºËÓвÎת¼×é²âÐò
ת¼×é¹ãÒåÉÏÖ¸ÌØ¶¨Ï¸°ûÔÚijһ¹¦Ð§×´Ì¬ÏµÄËùÓÐת¼²úÆ·£¬£¬£¬£¬°üÀ¨mRNA ºÍ·Ç±àÂëRNA£¨ncRNA£©¡£¡£¡£¡£ÊÇÅþÁ¬»ùÒò×éÒÅ´«ÐÅÏ¢ÓëÉúÎ﹦ЧµÄÒ»¶¨Å¦´ø¡£¡£¡£¡£ÕæºËÉúÎïת¼×é²âÐò»ùÓÚ¸ßͨÁ¿²âÐò£¬£¬£¬£¬¿É¿ìËÙ»ñµÃijһÎïÖÖÌØ¶¨Ï¸°û»ò×éÖ¯ÔÚijһ״̬ϵÄËùÓÐת¼±¾µÄÜöÝÍ£¬£¬£¬£¬ÓÃÓÚÑо¿»ùÒò½á¹¹ºÍ»ùÒò¹¦Ð§¡¢¿É±ä¼ô½ÓºÍÐÂת¼±¾Õ¹ÍûµÈ¡£¡£¡£¡£
ת¼×éÑо¿Äܹ»´ÓÕûÌåˮƽÑо¿»ùÒò¹¦Ð§ÒÔ¼°»ùÒò½á¹¹£¬£¬£¬£¬ÒѾ³ÉΪչÏÖÉúÎïÉú³¤·¢Óýµ÷¿ØºÍÄæ¾³Ð²ÆÈ˳Ӧ»úÖÆ¡¢ÉúÎï½ø»¯¼ÍÂÉ¡¢¼²²¡±¬·¢Éú³¤µÄÖ÷Òª»úÖÆÒÔ¼°·¢Ã÷Ö²¡»ùÒòµ÷¿ØµÄÒªº¦°ÐµãµÈ·½ÃæµÄÓÅÏÈÑо¿ÊֶΣ¬£¬£¬£¬ÏÖÔÚÒÑÆÕ±éÓ¦ÓÃÓÚ»ù´¡Ñо¿¡¢ÁÙ´²Õï¶ÏºÍÒ©ÎïÑз¢¡¢¶¯Ö²ÎïÓýÖֵȸ÷¸öÁìÓò¡£¡£¡£¡£
UG»·Çò×éѧÓÅÊÆ
1.È«Á÷³ÌЧÀÍ£º Ìṩ´ÓÉúÎïÑùÆ·µ½¿ÉÊÓ»¯Êý¾ÝµÄÈ«Ì××éѧЧÀÍ£»£»£»£»£»£»
2.¸»ºñÏîÄ¿ÂÄÀú£º¾ß±¸´¦Öóͷ£ÖØ´óÑù±¾µÄÄÜÁ¦£¬£¬£¬£¬Í¬Ê±¾ßÓи»ºñµÄ½¨¿âÂÄÀú£»£»£»£»£»£»
3.Á÷³Ì»¯ÆÊÎö£ºÍêÉÆµÄÆÊÎöÁ÷³Ì£¬£¬£¬£¬×¼È·¿ìËÙÆÊÎö×éѧÊý¾Ý£»£»£»£»£»£»±ðµÄ¿ÉÁ¬Ïµ¿Í»§µÄÐèÇóÎÞа¾ÙÐж¨ÖÆ»¯ÐÅÏ¢ÆÊÎö£»£»£»£»£»£»
4.רҵ»¯ÍŶӣº×ÊÉî¿ÆÑ§ÕÕÁϾßÓи»ºñµÄ¼Æ»®Éè¼Æ¡¢ÊÛºóЧÀÍÂÄÀú£¬£¬£¬£¬È«³ÌÒ»¶ÔÒ»Ïàͬ£»£»£»£»£»£»
5.һվʽ½â¾ö¼Æ»®£ºÓµÓÐһվʽ¶à×éѧЧÀÍ£¬£¬£¬£¬ÖúÁ¦»ù´¡Ñо¿¼°ÁÙ´²ÖÎÁÆ¡£¡£¡£¡£
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
¶¯Îï¼°ÁÙ´²ÔàÆ÷×éÖ¯/ÄÔ×éÖ¯µÈ |
>20mg |
¶¯Îï¼°ÁÙ´²Æ¤·ô/¹Ç/Ѫ¹Ü/Ö¬·¾×éÖ¯µÈ |
>100mg |
Ö²ÎïҶƬ×éÖ¯/»¨ |
>200mg |
Ö²Îï¸ù/¾¥/¹ûʵ/ÖÖ×Ó |
>500mg |
Ô´úϸ°û/ϸ°ûϵ |
>5×106¸ö |
ÖÐÐÔÁ£Ï¸°û/ÊÈËáÐÔÁ£Ï¸°û/ÊȼîÐÔÁ£Ï¸°û |
>5×107¸ö |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ×éÖ¯Ñù±¾½¨ÒéÉúÑÄÔÚRNAlater¡¢RNAHold¡¢RNAProtectµÈÏà¹Ø×éÖ¯ÉúÑÄÒºÖУ¬£¬£¬£¬È»ºó-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Ú ϸ°ûÑù±¾Ê¹ÓÃTRIzolµÈÁѽâÒº³ä·ÖÁѽâÖ®ºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ¡£¡£¡£¡£
ÉúÎïÐÅϢѧÆÊÎöÄÚÈÝ
Ó¦Óó¡¾°
Ó¦Óó¡¾°1£º²î±ð»ùÒòɸѡÓ빦ЧÆÊÎö
ÊÊÓùæÄ££ºÁÙ´²Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧ¡¢¶¯Ö²Îï¼°Õæ¾úÑо¿µÈí§ÒâÆ«Ïò
ʹÓÃÕæºËÓвÎת¼×é²âÐò£¬£¬£¬£¬¿Éͨ¹ý½ÏÁ¿ÊµÑé×éºÍ±ÈÕÕ×é»ùÒò±í´ïÁ¿É¸Ñ¡²î±ð±í´ïµÄ»ùÒò¡£¡£¡£¡£È»ºó¶Ô²î±ð±í´ï»ùÒò¾ÙÐнøÒ»²½Ëø¶¨£¬£¬£¬£¬Èçͨ¹ýGO¡¢KEGG¸»¼¯ÆÊÎö¼°GSEAÆÊÎö£¬£¬£¬£¬ÅäºÏPubmedÖÐÒѽÒÏþµÄÎÄÏ×ÒÔ¼°¿ÎÌâ×éÖÐÒÑ»ýÀ۵IJ¿Çå³þÐÇ·Ö×Ó¶Ô²î±ð±í´ï»ùÒò¾ÙÐй¦Ð§×¢ÊÍ£¬£¬£¬£¬²¢½øÒ»²½ÆÊÎö¹Ø×¢µÄ¹¦Ð§»ùÒò¡£¡£¡£¡£½øÈëʵÑéÑéÖ¤½×¶Îºó¿É¶Ôɸѡµ½µÄ²î±ð»ùÒò¾ÙÐÐqPCR¡¢Northern¡¢Western Blot¡¢FISHÑéÖ¤¡¢»ùÒòÇóý¼°¹ý±í´ïµÈ¡£¡£¡£¡£
Ó¦Óó¡¾°2£ºÊ±ÐòÆÊÎö»òŨ¶ÈÌÝ¶ÈÆÊÎö
ÊÊÓùæÄ££ºÁÙ´²Ñù±¾¡¢Ï¸°ûÑù±¾¡¢¶¯Ö²ÎïÑù±¾Óжà¸öʱ¼ä¶ÎµÄÑù±¾£¬£¬£¬£¬»ò²î±ðÒ©ÎïŨ¶È´¦Öóͷ£µÄÑù±¾
ÔÚת¼×éÊý¾ÝÆÊÎöÀú³ÌÖУ¬£¬£¬£¬ÓÐÒ»ÀàÌØÊâµÄʵÑéÉè¼Æ¡£¡£¡£¡£Í¨¹ý¶Ô²î±ðʱ¼ä¶ÎµÄʵÑéÑù±¾¾ÙÐÐËѼ¯£¬£¬£¬£¬»ò²âÊÔ²î±ðµÄÒ©Îï¡¢ÊÔ¼ÁµÈŨ¶ÈÌݶȵÄÑù±¾¾ÙÐÐÊÕÂÞ¡£¡£¡£¡£¼Ì¶øÑо¿²î±ð»ùÒòÔÚ²î±ðʱ¼ä¶Î»ò²î±ðŨ¶ÈÌݶȼäµÄ±í´ï¼ÍÂÉ£¬£¬£¬£¬ÕâÒ»ÀàÆÊÎöͨ³£³ÆÖ®Îª“ʱÐòÆÊÎö”
Ó¦Óó¡¾°3£º×ªÂ¼Òò×Ó/µ÷¿ØÒò×Ó/¼ôÇÐÒò×ÓµÈÉÏÓε÷¿Ø»ùÒòÍÚ¾ò
ÊÊÓùæÄ££ºÁÙ´²Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧ¡¢¶¯Ö²ÎïÑо¿µÈí§ÒâÑо¿Æ«Ïò
ͨÀýת¼×é²î±ðÆÊÎö¼«ÓпÉÄÜ»ñµÃ´ó×ڵIJî±ð»ùÒò£¬£¬£¬£¬Õâ¶ÔºóÆÚʵÑéÑéÖ¤µÄÄ¿µÄËø¶¨´øÀ´ÌôÕ½¡£¡£¡£¡£ÔÚûÓÐÌØ¶¨¸ÐÐËȤµÄͨ·¼°Ã÷ÐÇ·Ö×ÓÌõ¼þÏ£¬£¬£¬£¬×ªÂ¼Òò×ÓÊÇÒ»¸öºÜÊDz»´íµÄÇÐÈëÆ«Ïò¡£¡£¡£¡£×ªÂ¼Òò×Ó¿ÉÒÔµ÷Àí»ùÒò×éDNA¿ª·ÅÐÔ¡¢ÕÙļRNA¾ÛºÏø¾ÙÐÐת¼Àú³Ì¡¢ÕÙÖúÒò×Óµ÷ÀíÌØ¶¨µÄת¼½×¶Î£¬£¬£¬£¬µ÷¿ØÖî¶àÉúÃüÀú³Ì£¬£¬£¬£¬ÖîÈçÃâÒß·´Ó¦¡¢·¢ÓýģʽµÈ¡£¡£¡£¡£ÒÔÊÇ£¬£¬£¬£¬ÆÊÎöת¼Òò×Ó±í´ï¼°Æäµ÷¿Ø»îÐÔ¹ØÓÚÆÊÎöÖØ´óÉúÔËÆø¶¯¾ßÓÐÖ÷ÒªÒâÒå¡£¡£¡£¡£ÆäËûµ÷ÀíÒò×Ó°üÀ¨¿É±ä¼ôÇеȵ÷¿Ø»ùÒòÒ²¿ÉÒÔ¼ÓÈëÉÏÓε÷¿Ø¡£¡£¡£¡£
Ó¦Óó¡¾°4£º´óÑù±¾Ñо¿
ÊÊÓùæÄ££º¶¯Ö²ÎïÓýÖÖ¡¢ÒÅ´«ÈºÌåÓëÎïÖÖÆðÔ´¡¢ÈËȺÐÐÁÐÓëÉúÎï±ê¼ÇÎïÍÚ¾ò
Ëæ×ŲâÐòÊÖÒյķÉËÙÉú³¤£¬£¬£¬£¬ÉÙÁ¿Ñù±¾µÄת¼×é²âÐòÑо¿ÒѾÎÞ·¨Ú¹ÊÍÖØ´óµÄÉúÎïѧÎÊÌâ¡£¡£¡£¡£Ñо¿ÕßÃÇÒÑ×îÏÈʹÓôóÑù±¾Á¿µÄת¼×éÑù±¾£¬£¬£¬£¬Á¬ÏµÍ³¼ÆÑ§Óë»úеѧϰµÈ·½·¨£¬£¬£¬£¬ÖªµÀÇкÏÌØ¶¨¼ÍÂɺÍÑо¿Ä¿µÄµÄ½¹µã»ùÒò¡£¡£¡£¡£ÈçÃϵ¶ûËæ»ú»¯¡¢Ïà¹ØÐÔÆÊÎö¡¢ÏßÐԻع顢LASSO»Ø¹é¡¢Cox»Ø¹éµÈ£¬£¬£¬£¬ÆÊÎö²î±ðÑù±¾»ùÒò»ò»ùÒò×é¶àÑùÐÔ£¬£¬£¬£¬ÍÚ¾ò¸üÉîÈëºÍÖÜÈ«µÄÉúÎïѧÒâÒå¡£¡£¡£¡£
ÏîÄ¿ÎÄÕÂ
¡¾1¡¿Liang H, et al. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. Ann Transl Med. 2022 Mar;10(6):281. PMID: 35434017.
¡¾2¡¿Pi Y, et al. The role of PIWI-interacting RNA in naringin pro-angiogenesis by targeting HUVECs. Chem Biol Interact. 2023 Feb 1;371:110344. PMID: 36623717.
LncRNA²âÐò
³¤Á´·Ç±àÂëRNA£¨lncRNA£©ÊÇÒ»À೤¶È´óÓÚ200 nt µÄ·Ç±àÂëRNA£¨ncRNA£©£¬£¬£¬£¬ÆÕ±é±£´æÓÚÖÖÖÖÉúÎïÌåÄÚ£¬£¬£¬£¬ÔÚ±í¹ÛÒÅ´«µ÷¿Ø¡¢Ï¸°ûÖÜÆÚµ÷¿ØºÍϸ°û·Ö½âµ÷¿ØµÈÖÚ¶àÉúÔËÆø¶¯ÖÐʩչÖ÷Òª×÷Ó㬣¬£¬£¬Ó붯ֲÎïµÄÉú³¤·¢Óý£¬£¬£¬£¬ÈËÀàµÄ¼²²¡±¬·¢ÓÐ×ÅÇ×½ü¹ØÏµ£¬£¬£¬£¬Ò²¿É×÷Ϊ¼²²¡Õï¶ÏµÄ±ê¼ÇÎï»òÊÇÖ÷Òª°Ðµã¡£¡£¡£¡£
ʹÓøßͨÁ¿²âÐòÊÖÒÕ¾ÙÐÐlncRNA ²âÐò¼°ÉúÎïÐÅϢѧÆÊÎö£¬£¬£¬£¬¿É¿ìËÙ׼ȷµØ·¢Ã÷ÄÇЩ¾ßÓÐÖ÷Òªµ÷¿Ø¹¦Ð§µÄlncRNA£¬£¬£¬£¬ÆÊÎöÆäÓëÌØ¶¨ÉúÎïѧÀú³ÌµÄ¹ØÏµ£¬£¬£¬£¬ÉîÈë̽Ë÷lncRNAµÄ¹¦Ð§¼°Æä±í´ïµ÷¿Ø»úÖÆ¡£¡£¡£¡£°üÀ¨¾ºÕùÁ¬ÏµmiRNAµÄceRNAµ÷¿Ø»úÖÆ£¬£¬£¬£¬¼°¶ÔȾɫÖʽṹ¾ÙÐÐһϵÁе÷¿ØÈçÔöÇ¿×Ó¡¢Æô¶¯×Ó¡¢¾øÔµ×ӵȡ£¡£¡£¡£
ÊÖÒÕÓÅÊÆ
1. ÎÄ¿âÓÅ»¯£º½ÓÄɺËÌÇÌåÈ¥³ýºÍÁ´ÌØÒìÐÔÎĿ⹹½¨¼Æ»®£¬£¬£¬£¬±£´æÁËÍêÕûµÄlncRNAºÍmRNAÐòÁУ¬£¬£¬£¬ÒÔ¼°ÐòÁÐÆ«ÏòÐÔ¡£¡£¡£¡£
2. ÐòÁÐÍêÕû£º¶ÔÑù±¾ÖÐÏÕЩËùÓеÄlncRNAºÍmRNAÐòö¾ÙÐÐÅÐ¶ÏºÍÆÊÎö¡£¡£¡£¡£
3. ÎïÖÖ¶àÔª£º¶Ô°üÀ¨ÈËÀà¡¢¶¯Ö²ÎïÔÚÄÚµÄÐí¶àÎïÖÖµÄlncRNA¾ÙÐÐÅÐ¶ÏºÍÆÊÎö¡£¡£¡£¡£
4. ÆÊÎöÑϽ÷£ºÏµÍ³ÍøÂçlncRNAÊý¾Ý¿âÓÃÓÚÅжÏÒÑÖªlncRNA£¬£¬£¬£¬²¢ÉèÖÃÑÏ¿áµÄɸѡÌõ¼þÓÃÓÚ·¢Ã÷ÐÂlncRNA¡£¡£¡£¡£
5. ¹ØÁªÖÜÈ«£º¿ªÕ¹lncRNAÓëmRNAµÄ¹ØÁªÆÊÎö£¬£¬£¬£¬ÉîÈëÆÊÎölncRNAµ÷¿ØÍøÂç¡£¡£¡£¡£
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
¶¯Îï¼°ÁÙ´²ÔàÆ÷×éÖ¯/ÄÔ×éÖ¯µÈ |
>20mg |
¶¯Îï¼°ÁÙ´²Æ¤·ô/¹Ç/Ѫ¹Ü/Ö¬·¾×éÖ¯µÈ |
>100mg |
Ö²ÎïҶƬ×éÖ¯/»¨ |
>200mg |
Ö²Îï¸ù/¾¥/¹ûʵ/ÖÖ×Ó |
>500mg |
Ô´úϸ°û/ϸ°ûϵ |
>5×106¸ö |
ÖÐÐÔÁ£Ï¸°û/ÊÈËáÐÔÁ£Ï¸°û/ÊȼîÐÔÁ£Ï¸°û |
>5×107¸ö |
ÍâÃÚÌåÑù±¾ |
>1×108¸ö |
ѪÇå/Ѫ½¬/ÄÔ¼¹Òº/ÊàŦ»ýÒº/ÂÑÅÝÒº |
>2mL |
ϸ°û×÷ÓýÉÏÇåÒº |
>20mL |
ÄòÒº |
>30mL |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ×éÖ¯Ñù±¾½¨ÒéÉúÑÄÔÚRNAlater¡¢RNAHold¡¢RNAProtectµÈÏà¹Ø×éÖ¯ÉúÑÄÒºÖУ¬£¬£¬£¬È»ºó-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Ú ϸ°ûÑù±¾Ê¹ÓÃTRIzolµÈÁѽâÒº³ä·ÖÁѽâÖ®ºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ
Ó¦Óó¡¾°
Ó¦Óó¡¾°1£ºÆô¶¯×Ó/ÔöÇ¿×Óµ÷¿Ø
ÊÊÓùæÄ££º·ÇÏßÐÔת¼µ÷¿Ø¡¢ÐÂ˳ʽ×÷ÓÃÔª¼þ·¢Ã÷¼°¹¦Ð§Åжϡ¢×éÖ¯ÌØÒìÐÔÆô¶¯×Óɸѡ¼°È·¶¨µÈÑо¿
lncRNAµÄ×ÔÉíת¼»á×ÌÈÅÆäÏà½ü±àÂëÂѰ׵ĻùÒòµÄת¼¡£¡£¡£¡£ÉÏÓÎlncRNAת¼ʱ£¬£¬£¬£¬»á´©Ô½Ïà½ü°Ð»ùÒòµÄÆô¶¯×ÓÇø£¬£¬£¬£¬×ÌÈÅÁËת¼Òò×ÓÓë°Ð»ùÒòµÄÆô¶¯×ÓÁ¬Ïµ£¬£¬£¬£¬´Ó¶øÒÖÖÆ°Ð»ùÒòµÄת¼¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬lncRNA¾ßÓÐÔö½øÔöÇ¿×Ó»·»¯ºÍ¼¤»î»ùÒò±í´ïµÄ¹¦Ð§¡£¡£¡£¡£ÔÚûÓгɻ·µÄÇéÐÎÏÂÔöÇ¿×Ó´¦ÓÚ·Ç»îÐÔ״̬¡£¡£¡£¡£
Ó¦Óó¡¾°2£ºÓëÂѰ×ÐÞÊÎ/DNA¼×»ù»¯/m6AÁªºÏ
ÊÊÓùæÄ££ºÁÙ´²Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢Ö²ÎïÒÅ´«ÓýÖÖµÈÑо¿
lncRNA¼ÓÈë±í¹Ûµ÷¿Ø£¬£¬£¬£¬¿ÉÄÜÊÇÕÐļһЩȾɫÖÊÖØ¹¹¸´ºÏÌåÀ´½éµ¼»ùÒòĬȻ£¬£¬£¬£¬ÓÈÆäÊÇһЩÓë×éÂѰ×ÐÞÊÎÏà¹ØµÄ×éÂѰ׼׻ù×ªÒÆÃ¸µÄµ÷¿Ø¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬lncRNA»¹ÄÜÓëһЩDNA¼×»ù»¯ºÍÈ¥¼×»ù»¯Ã¸Á¬ÏµÊ¹µÃ»ùÒòµÄÆô¶¯×ÓÇø±¬·¢¼×»ù»¯µÄת±ä´Ó¶øÓ°Ïì»ùÒò±í´ï¡£¡£¡£¡£
Ó¦Óó¡¾°3£ºceRNAµ÷¿Ø»úÖÆ
ÊÊÓùæÄ££ºÇéÐÎÓ¦¼¤¡¢ÁÙ´²Ò½Ñ§¡¢Ö²ÎïÒÅ´«ÓýÖÖ¡¢¼²²¡ÔçÆÚÕï¶ÏµÈÑо¿
ceRNAÈ«³Æcompeting endogenous RNA£¬£¬£¬£¬ÊÇÒ»ÖÖÄܹ»¾ºÕùÁ¬ÏµRNAµÄ×÷ÓÃÔª¼þ¡£¡£¡£¡£Í¨³£lncRNAºÍcircRNA»á¾ºÕùÁ¬ÏµmiRNA£¬£¬£¬£¬ÎÒÃÇÒ»Ñùƽ³£°ÑlncRNAºÍcircRNA¿ÉÒÔ³Æ×÷ceRNA¡£¡£¡£¡£ceRNAµ÷¿ØÍøÂçÈ«³ÆceRNAregulation network£¬£¬£¬£¬Ö¸µÄÊÇÓÐceRNA¼ÓÈëµÄÕû¸öµ÷¿ØÍøÂçcascade¡£¡£¡£¡£¶øceRNAÆÊÎöÖ¸µÄÊǶÔÕû¸öceRNAµ÷¿ØÍøÂç¾ÙÐÐÆÊÎö¡£¡£¡£¡£Ò»Ñùƽ³£ÓÐcircRNA-miRNA-mRNAÆÊÎö»òlncRNA-miRNA-mRNAÆÊÎö¡£¡£¡£¡£
Ч¹ûչʾ
²î±ðÑù±¾lncRNA»ùÒò×é¿ÉÊÓ»¯Ð§¹ûΪÁ˸üÖ±¹ÛµÄչʾlncRNA candidateÔÚȾɫÌåÖÐÂþÑÜÇéÐΣ¬£¬£¬£¬ÎÒÃǽÓÄÉcircos(ww.circos.ca)Èí¼þ¶Ôɸѡ»ñµÃµÄlncRNA¾ÙÐлùÒò×émapping¡£¡£¡£¡£
Ö÷Òª·ÖΪÁ½²¿·Ö¾ÙÐÐչʾ£¬£¬£¬£¬Ò»²¿·Öƾ֤lncRNAµÄ²î±ð·ÖÀà¾ÙÐлùÒò×émapping£¬£¬£¬£¬ÁíÒ»²¿·Öƾ֤²î±ðÑù±¾ÖÐlncRNA¾ÙÐлùÒò×émapping¡£¡£¡£¡£×÷ͼʱ»®·Ö½«Ã¿ÌõȾɫÌåÆ¾Ö¤Ã¿25mbΪ»ù±¾µ¥Î»£¬£¬£¬£¬²î±ðÑù±¾ÖÐlncRNA»ùÒò×é¿ÉÊÓ»¯×÷ͼʱͳ¼ÆÃ¿¸öÇø¶ÎÖÐlncRNAµÄ±í´ïÁ¿»æÍ¼£¬£¬£¬£¬²î±ðlncRNAÀàÐÍ»ùÒò×é¿ÉÊÓ»¯Ê±Í³¼ÆÃ¿¸öÇø¶ÎÄÚlncRNAµÄÊýÄ¿»æÍ¼¡£¡£¡£¡£
1.²î±ð»ùÒò»ðɽͼ
ͨ¹ý»æÖÆ»ðɽͼ¿ÉÒÔÏàʶ²î±ð±í´ï»ùÒòµÄÕûÌåÂþÑÜÇéÐΡ£¡£¡£¡£ÒÔlog2 (foldchange)Ϊºá×ø±ê£¬£¬£¬£¬-log10(pvalue)Ϊ×Ý×ø±ê£¬£¬£¬£¬¶Ô²î±ð±í´ïÆÊÎöÖÐËùÓеĻùÒò»æÖÆ»ðɽͼ¡£¡£¡£¡£ ÆäÖкá×ø±ê´ú±í»ùÒòÔÚ²î±ðÑù±¾Öвî±ð±í´ï±¶Êýת±ä£»£»£»£»£»£»×Ý×ø±ê´ú±í»ùÒò±í´ïÁ¿×ª±ä²î±ðµÄͳ¼ÆÑ§ÏÔÖøÐÔ£»£»£»£»£»£»upÑÕÉ«´ú±íÉϵ÷µÄÏÔÖø²î±ð±í´ï»ùÒò£¬£¬£¬£¬downÑÕÉ«´ú±íϵ÷µÄÏÔÖø²î±ð±í´ï»ùÒò£¬£¬£¬£¬no´ú±í·ÇÏÔÖøÐÔ²î±ð±í´ï»ùÒò¡£¡£¡£¡£
2.²î±ð»ùÒò¾ÛÀàÈÈͼ
²î±ð»ùÒò¾ÛÀàÆÊÎöÓÃÓÚÅжϻùÒòÔÚ²î±ðʵÑéÌõ¼þϵ÷¿ØÄ£Ê½µÄ¾ÛÀàģʽ¡£¡£¡£¡£Æ¾Ö¤ÑùÆ·»ùÒò±í´ïÆ×µÄÏà½üˮƽ£¬£¬£¬£¬½«»ùÒò¾ÙÐоÛÀàÆÊÎö£¬£¬£¬£¬Ö±¹ÛµØÕ¹Ê¾»ùÒòÔÚ²î±ðÑùÆ·£¨»òÊDzî±ð´¦Öóͷ££©Öеıí´ïÇéÐΣ¬£¬£¬£¬ÓÉ´Ë»ñÈ¡ÉúÎïѧÏà¹ØÐÅÏ¢¡£¡£¡£¡£ÎªÁ˸üºÃµÄÖ±¹Û·´Ó¦¾ÛÀà±í´ïģʽ£¬£¬£¬£¬¹ØÓÚ·ÇÉúÎïÑ§ÖØ¸´
ÎÒÃǽÓÄÉlog10(FPKM+1)¾ÙÐÐչʾ£¬£¬£¬£¬¹ØÓÚÉúÎïÑ§ÖØ¸´½«²î±ð»ùÒòFPKMͨ¹ýZÖµ·½·¨¾ÙÐлùÒò±í´ïչʾ¡£¡£¡£¡£ÆäÖкá×ø±êΪÑù±¾£¬£¬£¬£¬×Ý×ø±êΪ»ùÒò£¬£¬£¬£¬²î±ðµÄÑÕÉ«ÌåÏÖ²î±ðµÄ»ùÒò±í´ïˮƽ¡£¡£¡£¡£
³£¼ûÎÊÌâ
1.ʲôÊdz¤Á´·Ç±àÂëRNA£¿£¿ËüÃǵÄ×÷ÓÃÓÐÄÄЩ£¿£¿
²¸È鶯Îï»ùÒò×éÐòÁеÄÔ¼5%¡«10%±»ÎȹÌת¼£¬£¬£¬£¬ÂѰ×ÖʱàÂë»ùÒò½öÔ¼Õ¼1%£¬£¬£¬£¬ÆäÓà4%¡«9%µÄÐòÁж¼×ªÂ¼Îª·Ç±àÂëRNA¡£¡£¡£¡£¶ø·Ç±àÂëRNA(non-coding RNA) ÊÇÖ¸²»¿É·ÒëΪÂѰ׵Ĺ¦Ð§ÐÔRNA·Ö×Ó¡£¡£¡£¡£³¤Á´·Ç±àÂëRNAΪÕâ4%¡«9%Öг¤¶È´óÓÚ200ntµÄ·Ç±àÂëRNA¡£¡£¡£¡£ËüÃǵÄ×÷ÓÃÖ÷ÒªÌåÏÖÔÚËĸö·½Ã棺µÚÒ»£¬£¬£¬£¬Ó°ÏìÖܱ߻ùÒòµÄ±í´ï£»£»£»£»£»£»µÚ¶þ£¬£¬£¬£¬µ÷¿ØÂѰ×ÖÊÔ˶¯¼°¶¨Î»£»£»£»£»£»£»µÚÈý£¬£¬£¬£¬±¬·¢Ð¡·Ö×ÓRNA£»£»£»£»£»£»µÚËÄ£¬£¬£¬£¬¶ÔÆäËûRNAµÄµ÷¿Ø×÷Óᣡ£¡£¡£
2.lncRNA²âÐòΪʲôÐèÒª¹¹½¨Á´ÌØÒìÐÔÎĿ⣿£¿
Ðí¶à»ùÒò×éÇøÓò¾ßÓÐÕý¸ºÁ´µÄת¼±¾£¬£¬£¬£¬·´Òåת¼ÊÇÕæºË»ùÒòµÄÒ»¸öÌØÕ÷£¬£¬£¬£¬ÊÇÒ»ÖÖÖ÷ÒªµÄµ÷¿Ø·½·¨¡£¡£¡£¡£Ê¹ÓÃssRNA-Seq£¨Strand-Specific£©Äܹ»±£´æRNAµÄÆ«ÏòÐÔÐÅÏ¢£¬£¬£¬£¬¿ÉÒÔÈ·¶¨×ªÂ¼ÔÀ´×ÔÕýÁ´ÕվɸºÁ´£¬£¬£¬£¬ÒÔ±ãÔ½·¢×¼È·µÄ»ñµÃ»ùÒòµÄ½á¹¹ÒÔ¼°»ùÒò±í´ïÐÅÏ¢¡£¡£¡£¡£
3.Õ¹ÍûlncRNAÓëmRNA¡¢miRNA»¥×÷µÄÒªÁ죿£¿
1£©cisµ÷¿ØÕ¹Íû£¬£¬£¬£¬É¸Ñ¡µÄÌõ¼þÖ»ÓÐcis locationÊÇ100kb¡£¡£¡£¡££¨Í³Ò»ÌõȾɫÌåÉϾàÀëlncRNA100kbµÄmRNA£¬£¬£¬£¬¶¼»á±»ÁÐÈëµ½cisµ÷¿ØµÄ¿ÉÄÜ£©
2£©transµ÷¿ØÕ¹ÍûÓõÄÊÇRIsearchÈí¼þ£¬£¬£¬£¬ÊÇÒÔ×îС×ÔÓÉÄÜСÓÚ-11À´É¸Ñ¡¼î»ù»¥²¹Åä¶ÔµÄlncRNAÓëmRNA¡£¡£¡£¡£
3£©ÔÚÕ¹ÍûlncRNAÓëmiRNA»¥×÷µÄʱ¼ä£¬£¬£¬£¬ ÓÃscore·£·ÖÖµÀ´Åжϣ¬£¬£¬£¬Ò»Ñùƽ³£≤4¾ÍÈ϶¨Îª¿ÉÐÅ£¬£¬£¬£¬ÊýֵԽСԽ¿ÉÐÅ¡£¡£¡£¡£
CircRNA²âÐò
¹²¼Û±ÕºÏ¡¢µ¥Á´»·×´µÄRNA£¨circRNA£©ÊÇÒ»Àà½ÏÁ¿ÌØÊâµÄRNA£¬£¬£¬£¬ÆäûÓÐÓÎÀëµÄ5′ñ×ӽṹºÍ3′ poly£¨A£©½á¹¹£¬£¬£¬£¬²¢ÇÒ¶ÔºËËáø²»Ãô¸Ð£¬£¬£¬£¬Òò´Ë±ÈͨË×µÄÏßÐÔRNA£¨linear RNA£©¸üÎȹ̡£¡£¡£¡£Ëæ×ŸßͨÁ¿²âÐòÒÔ¼°ÉúÎïÐÅÏ¢ÆÊÎöÊÖÒյĿìËÙÉú³¤£¬£¬£¬£¬ÔÚ²î±ðÎïÖÖÖÐÅжϳö³ÉǧÉÏÍò¸öcircRNA£¬£¬£¬£¬ÆäÖдó´ó¶¼circRNA ÔÚ²î±ðÎïÖÖ¼ä¾ßÓÐÊØ¾ÉÐÔºÍÎȹÌÐÔ£¬£¬£¬£¬²¢ÇÒcircRNA µÄ±í´ï¾ßÓÐϸ°ûÌØÒìÐÔ¡¢×éÖ¯ÌØÒìÐÔÒÔ¼°·¢Óý½×¶ÎÌØÒìÐÔ¡£¡£¡£¡£circRNA³ýÁËͨÀýµÄ¶ÔmiRNA¾ºÕùÁ¬ÏµµÄceRNAµ÷¿Ø»úÖÆÍ⣬£¬£¬£¬ÉÐÓзÒë¶àëĵÈй¦Ð§£¬£¬£¬£¬ÔÚҽѧ¼°¶¯Ö²Îï»ù´¡Ñо¿¼°ºóÆÚת»¯ÉÏÓÐ×ÅÖØ´óµÄDZÁ¦¡£¡£¡£¡£
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
¶¯Îï¼°ÁÙ´²ÔàÆ÷×éÖ¯/ÄÔ×éÖ¯µÈ |
>20mg |
¶¯Îï¼°ÁÙ´²Æ¤·ô/¹Ç/Ѫ¹Ü/Ö¬·¾×éÖ¯µÈ |
>100mg |
Ö²ÎïҶƬ×éÖ¯/»¨ |
>200mg |
Ö²Îï¸ù/¾¥/¹ûʵ/ÖÖ×Ó |
>500mg |
Ô´úϸ°û/ϸ°ûϵ |
>5×106¸ö |
ÖÐÐÔÁ£Ï¸°û/ÊÈËáÐÔÁ£Ï¸°û/ÊȼîÐÔÁ£Ï¸°û |
>5×107¸ö |
ÍâÃÚÌåÑù±¾ |
>1×108¸ö |
ѪÇå/Ѫ½¬/ÄÔ¼¹Òº/ÊàŦ»ýÒº/ÂÑÅÝÒº |
>2mL |
ϸ°û×÷ÓýÉÏÇåÒº |
>20mL |
ÄòÒº |
>30mL |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ×éÖ¯Ñù±¾½¨ÒéÉúÑÄÔÚRNAlater¡¢RNAHold¡¢RNAProtectµÈÏà¹Ø×éÖ¯ÉúÑÄÒºÖУ¬£¬£¬£¬È»ºó-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Ú ϸ°ûÑù±¾Ê¹ÓÃTRIzolµÈÁѽâÒº³ä·ÖÁѽâÖ®ºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ
Ó¦Óó¡¾°
Ó¦Óó¡¾°1£º½á¹¹·Ö×ÓÕÐļ½¹µãÂѰ×ÓëºËËá
ÊÊÓùæÄ££º»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧµÈí§ÒâÑо¿Æ«Ïò
lncRNAºÍcircRNAÓÐʱ¼ä»á×÷ΪһÖÖÌØÊâµÄRNA·Ö×Ó£¬£¬£¬£¬ÐγÉÂѰ×-ÂѰ׸´ºÏÎï»òÂѰ×-ºËËáµÄ¹Ç¼Ü·Ö×Ó£¬£¬£¬£¬¶ÔÏÂÓηÖ×ÓÐÐʹһϵÁе÷¿Ø×÷Óᣡ£¡£¡£È粿·ÖcircRNA»áÕÐļһЩ·ºËØ»¯Ã¸¶ÔÏÂÓεÄÂѰ×ÐÐʹ½µ½â¹¦Ð§£¬£¬£¬£¬»òÕß²¿·ÖlncRNA»áÕÐļһЩת¼Òò×ÓÓëÄ¿µÄ»ùÒòµÄÆô¶¯×ÓÇøÓòÁ¬Ïµ¼¤»îÏÂÓεĻùÒò±í´ïµÈ¡£¡£¡£¡£
Ó¦Óó¡¾°2£ºÍâÃÚÌå
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§µÈí§ÒâÑо¿Æ«Ïò
lncRNAÔÚÍâÃÚÌåÖÐÓÉÓÚÒÔË鯬ÐÎʽ±£´æ£¬£¬£¬£¬ÕâÖÖËæ»úƬ¶Ï²»µ«µ¹ÔËÓÚ¼ì²â£¬£¬£¬£¬²¢Çҽϵ͵ÄŨ¶ÈºÍ½Ï²îµÄÖØ¸´ÐÔ£¬£¬£¬£¬Ê¹µÃlncRNA²¢²»ÊÇÍâÃÚÌåÑо¿µÄÈÈÃÅ·Ö×ÓÖ®Ò»¡£¡£¡£¡£¿ÉÊÇcircRNAÓÉÓÚÆäÎȹÌÐÔ£¬£¬£¬£¬³ýÁË´ÓÌåÒºÑù±¾ÍâÃÚÌåÖÐÊèÉ¢circRNA¿É×÷Ϊ¼²²¡±ê¼ÇÎïÍ⣬£¬£¬£¬»¹ÄÜÓÃÓÚºóÆÚµÄÍâÃÚÌåÖÎÁƵÈÁìÓò£¬£¬£¬£¬ÊǺóceRNAʱ´úÖнÏΪÈÈÃŵÄcircRNAϸ·ÖÑо¿ÁìÓòÆ«ÏòÖ®Ò»¡£¡£¡£¡£ÆäÖÐÒ»¸öÆ«ÏòÊǼ²²¡±ê¼ÇÎ£¬£¬£¬Ò»Ñùƽ³£ÒÔ´óÑù±¾ÐÐÁÐÑо¿¾Ó¶à¡£¡£¡£¡£Ò»ÖÖÊǺóÆÚת»¯¼°»úÖÆÑо¿Æ«Ïò£¬£¬£¬£¬°üÀ¨ÍâÃÚÌåÊÜÌåϸ°û·Ö×Ó»úÖÆÑо¿ÒÔ¼°¼²²¡ÖÎÁÆµÈÆ«Ïò¡£¡£¡£¡£
Ó¦Óó¡¾°3£º·Òë¶àëÄ
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧµÈí§ÒâÑо¿Æ«Ïò
circRNAÉÏÓÐÒ»¶Îδ·ÒëµÄRNAÐòÁУ¬£¬£¬£¬³ÆÎªIRES£¬£¬£¬£¬Ëü¿ÉÒÔÕÛµþ³ÉÀàËÆÓÚÆðʼtRNAµÄ½á¹¹£¬£¬£¬£¬²¢ÕÐļ¸ü¶àµÄºËÌÇÌå¡£¡£¡£¡£Õý³£ÇéÐÎÏ£¬£¬£¬£¬IRES²»ÓëeIFÁ¬Ïµ£¬£¬£¬£¬¶øÊÇÓëÒ»Àà³ÆÎªITAFµÄÂѰ×ÖÊÁ¬Ïµ¡£¡£¡£¡£ITAFµÄ×÷ÓÃÊǽ«ºËÌÇÌåÕÙļµ½circRNAµÄÄÚ²¿½á¹¹£¬£¬£¬£¬ÒÔÆô¶¯ÂѰ×ÖÊ·Òë¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬»¹¿ÉÄܱ£´æIRESÔöÇ¿×Ó£¬£¬£¬£¬ÀàËÆÓÚcirc-ZNF609µÄUTRÔª¼þ¡£¡£¡£¡£Ò²ÓÐÑо¿Í¨¹ý·Òë×é²âÐòÓëת¼×é²âÐò£¬£¬£¬£¬·¢Ã÷Á˷DZàÂëRNA LINC-PINTÐγɻ·×´RNAºó¿É±»·ÒëÐÎÀÖ³ÉÄܶàëÄ¡£¡£¡£¡£
Ó¦Óó¡¾°4£ºceRNAµ÷¿Ø»úÖÆ
ceRNAÈ«³Æcompeting endogenous RNA£¬£¬£¬£¬ÊÇÒ»ÖÖÄܹ»¾ºÕùÁ¬ÏµRNAµÄ×÷ÓÃÔª¼þ¡£¡£¡£¡£Í¨³£lncRNAºÍcircRNA»á¾ºÕùÁ¬ÏµmiRNA£¬£¬£¬£¬ÎÒÃÇÒ»Ñùƽ³£°ÑlncRNAºÍcircRNA¿ÉÒÔ³Æ×÷ceRNA¡£¡£¡£¡£ceRNAµ÷¿ØÍøÂçÈ«³ÆceRNAregulation network£¬£¬£¬£¬Ö¸µÄÊÇÓÐceRNA¼ÓÈëµÄÕû¸öµ÷¿ØÍøÂçcascade¡£¡£¡£¡£¶øceRNAÆÊÎöÖ¸µÄÊǶÔÕû¸öceRNAµ÷¿ØÍøÂç¾ÙÐÐÆÊÎö¡£¡£¡£¡£Ò»Ñùƽ³£ÓÐcircRNA-miRNA-mRNAÆÊÎö»òlncRNA-miRNA-mRNAÆÊÎö¡£¡£¡£¡£
°¸Àýչʾ
circRNAºÍĸ»ùÒòͨ¹ý²î±ðµÄpathwayÓ°Ïì¸Î°©Ï¸°ûµÄÉú³¤£¬£¬£¬£¬Ç¨áãºÍÇÖÏ®
1.Ñо¿Åä¾°
¸Îϸ°û°©£¨HCC£©ÊÇ×î³£¼ûµÄÒ»ÖÖ¶ñÐÔÖ×Áö£¬£¬£¬£¬Í¬Ê±£¬£¬£¬£¬ÖйúÒ²ÊǸΰ©µÄ°©Ö¢´ó¹ú¡£¡£¡£¡£ËäÈ»ÏÖÔÚµÄÒ½ÁÆÕï¶ÏÊÖÒÕÉú³¤ºÜ¿ì£¬£¬£¬£¬¿ÉÊÇ£¬£¬£¬£¬¶ÔÓë¸Î°©µÄÏÖÓÐÕï¶ÏÊÖÒÕÕÕ¾ÉÊÜÏ޺ܴ󡣡£¡£¡£Òò´Ë£¬£¬£¬£¬¿ª·¢ÐµÄÕï¶Ïbiomarker£¬£¬£¬£¬²¢Ã÷È·ÕâЩbiomarkerµÄ×÷ÓûúÖÆ£¬£¬£¬£¬ÊÇÐí¶à¿ÆÑÐÖ°Ô±Ïë×öµÄÊÂÇé¡£¡£¡£¡£±¾Ñо¿´ÓcircRNA£¬£¬£¬£¬Ò»ÀàºÜÊÇÊʺÏ×öbiomarkerµÄºòÑ¡·Ö×Ó³ö·¢£¬£¬£¬£¬ÉîÈëÑо¿ÁËÒ»¸öпָ¼Ò×å»ùÒòZKSCAN1¼°Æä±¬·¢µÄcircZKSCAN1£¬£¬£¬£¬ÔÚHCCÖеÄ×÷ÓûúÖÆ¼°×÷ΪbiomarkerµÄDZÔÚ¼ÛÖµ¡£¡£¡£¡£
2.Ñо¿Ð§¹û
1)»ùÒò±í´ïģʽÆÊÎö
ZKSCAN1£¬£¬£¬£¬ÊÇÒ»¸öпָÂѰ׼Ò×壬£¬£¬£¬¸Ã¼Ò×å»ùÒòÔÚÖ×Áö±¬·¢£¬£¬£¬£¬Éú³¤£¬£¬£¬£¬×ªÒƺÍÒ©ÎïÄÍÊÜ·½Ã涼ʩչןÜÊÇÖ÷ÒªµÄ×÷Óᣡ£¡£¡£Í¬Ê±£¬£¬£¬£¬ÏÖÓеÄÑо¿Ò²·¢Ã÷£¬£¬£¬£¬ZKSCAN1»ùÒòµÄµÚ¶þ¸öºÍµÚÈý¸öÍâÏÔ×Ó²¿·ÖÄÜÐγÉÒ»¸öcircRNA£¬£¬£¬£¬ÔÚÈËÄÔ²¿ºÍ¸ÎÔà±í´ï¸»ºñ¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±Ê×ÏÈÑéÖ¤ÁËZKSCAN1ºÍcirc ZKSCAN1ÔÚHCC×éÖ¯Öеıí´ïÇéÐΡ£¡£¡£¡£102¸öHCC×éÖ¯ºÍÅä¶Ô°©ÅÔµÄRT-PCRЧ¹ûÏÔʾ£¬£¬£¬£¬ËûÃÇÔÚHCCÑù±¾Öеıí´ïÏÔÖø½µµÍ¡£¡£¡£¡£½øÒ»²½½«ZKSCAN1ºÍcirc ZKSCAN1µÄ±í´ïÓëÁÙ´²Ö¸±ê¾ÙÐйØÁªÆÊÎö£¬£¬£¬£¬·¢Ã÷µÍµÄZKSCAN1±í´ïÓëÖ×Áö¾ÞϸÏÔÖøÏà¹Ø£»£»£»£»£»£»¶øcirc ZKSCAN1µÄ±í´ïÓë²î±ðÖ×ÁöÊýÄ¿£¬£¬£¬£¬Ó²»¯Ë®Æ½£¬£¬£¬£¬Ñª¹ÜÇÖÏ®£¬£¬£¬£¬Î¢Ñª¹ÜÇÖÏ®£¬£¬£¬£¬Ö×Áögrade¶¼ÏÔÖøÏà¹Ø¡£¡£¡£¡£ROCÇúÏ߯ÊÎöÏÔʾ£¬£¬£¬£¬circ ZKSCAN1µÄAUCÖµµÖ´ï0.834£¬£¬£¬£¬Ãô¸ÐÐÔºÍÌØÒìÐÔÄִܵï82.2%ºÍ72.4%£¬£¬£¬£¬Ïà±È¶øÑÔ£¬£¬£¬£¬ZKSCAN1µÄAUCÖµÖ»ÓÐ0.474¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬circ ZKSCAN1µÄ±í´ï¸üºÏÊÊ×÷ΪÖ×Áö×éÖ¯µÄÕï¶Ïbiomarker¡£¡£¡£¡£

2)circRNAÓëĸ»ùÒò±í´ïÏà¹ØÐÔÆÊÎö
¹ØÓÚcircRNAµÄÑо¿£¬£¬£¬£¬µÚÒ»¸öÏëµ½µÄÊÇcircRNAµÄ±í´ïÊÇ·ñ»áºÍĸ»ùÒò±í´ïÓйØÁª¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±ÏÈÔÚ²î±ðÈËHCCϸ°ûϵÖмì²âÁËZKSCAN1 mRNAºÍcircZKSCAN1µÄ±í´ï¡£¡£¡£¡£·¢Ã÷ËùÓеÄϸ°ûϵ£¨Huh7, SMMC-7721, BEL-7402, HepG2ºÍHepG3B£©Ïà±È±ÈÕÕ×飨L02£©£¬£¬£¬£¬±í´ï¶¼½µµÍ¡£¡£¡£¡£Í¨¹ýÔÚHepG2ºÍSMMC7721Öйý±í´ïºÍÇýµZKSCAN1ºÍcircZKSCAN1£¬£¬£¬£¬Ñо¿Ö°Ô±·¢Ã÷¹ý±í´ï»òÕßÇýµÆäÖÐÒ»¸ö£¬£¬£¬£¬²»»áÓ°ÏìÁíÒ»¸öµÄ±í´ïת±ä¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬ZKSCAN1 mRNAºÍcircZKSCAN1µÄ±í´ïÏ໥×ÔÁ¦£¬£¬£¬£¬²»Ï໥ӰÏì¡£¡£¡£¡£

3)»ùÒò¹¦Ð§ÆÊÎö
Ϊ̽ÌÖZKSCAN1 mRNAºÍcircZKSCAN1¶ÔHCCϸ°ûµÄ¹¦Ð§Ó°Ï죬£¬£¬£¬Ñо¿Ö°Ô±¾ÙÐÐÁËÏà¹Ø¼ì²â¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬ÔÚZKSCAN1 mRNAºÍcircZKSCAN1µÄÇýµÏ¸°ûÖУ¬£¬£¬£¬ÔöÖ³ÄÜÁ¦ÏÔÖøÔöÇ¿£¬£¬£¬£¬¶ø¹ý±í´ïϸ°ûÖУ¬£¬£¬£¬ÏÔÖøÏ½µ£»£»£»£»£»£»¹ý±í´ïϸ°ûµÄǨáãºÍÇÖÏ®ÄÜÁ¦ÏÔÖø½µµÍ£»£»£»£»£»£»ÇýµÏ¸°ûÏÔÖøÔöÌí¡£¡£¡£¡£½øÒ»²½µÄÂãÊóݪֲʵÑéÒ²Åú×¢£¬£¬£¬£¬¹ý±í´ïʱÖ×ÁöÉú³¤ÒÖÖÆ£¬£¬£¬£¬¶øÇýµÊ±´Ì¼¤Ö×ÁöÉú³¤¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬ZKSCAN1 mRNAºÍcircZKSCAN1¶ÔÖ×ÁöÉú³¤ÓÐÏÔÖøÓ°Ïì¡£¡£¡£¡£

4)»ùÒòÑÇϸ°û¶¨Î»
»ùÒòÔÚϸ°ûÖеĶ¨Î»ÍùÍù¾öÒé×ÅËûÃǵĹ¦Ð§ÐÐʹ¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±¶ÔZKSCAN1µÄÂѰ׾ÙÐÐÑÇϸ°û¶¨Î»¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬Õý³£¸Î×éÖ¯µÄϸ°ûÖÊÖб£´æ´ó×ÚµÄZKSCAN1£¬£¬£¬£¬¶øHCC¸Î×éÖ¯ÖÐÈ´ºÜÉÙ¡£¡£¡£¡£ÁíÍ⣬£¬£¬£¬FISHÆÊÎöÅú×¢circ ZKSCAN1Ò²ÊÇÖ÷Òª¶¨Î»ÓÚϸ°ûÖÊÖС£¡£¡£¡£
5)ÏÂÓε÷¿Ø»ùÒòÆÊÎö
Ϊ̽ÌÖZKSCAN1µ÷¿ØÏ¸°ûÔöÖ³ºÍÇÖÏ®µÄÄÚÔÚ·Ö×Ó»úÖÆ¡£¡£¡£¡£Ñо¿Ö°Ô±¶ÔÇýµZKSCAN1 mRNAºÍcirc ZKSCAN1µÄHCCϸ°ûÓë±ÈÕÕ¾ÙÐÐÁËÈ«»ùÒò×éRNA²âÐò¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬ÇýµcircZKSCAN1ÒýÆð372¸ö»ùÒò²î±ð±í´ï£»£»£»£»£»£»ÇýµZKSCAN1ÒýÆð346¸ö»ùÒò²î±ð±í´ï¡£¡£¡£¡£ÆäÖУ¬£¬£¬£¬Á½×éЧ¹ûÖй²ÓÐ166¸öÊÇÔÚÁ½ÖÖÇéÐÎ϶¼·ºÆð²î±ð¡£¡£¡£¡£KEGGͨ·ÆÊÎöÏÔʾ£¬£¬£¬£¬Çýµcirc ZKSCAN1µÄ²î±ð»ùÒò¸»¼¯µ½PI3K pathway, migration pathway, actin cytoskeleton pathwayµÈ£»£»£»£»£»£»¶øÇýµZKSCAN1ÔòÖ÷Òª¸»¼¯µ½metabolic pathways¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬circ ZKSCAN1ºÍZKSCAN1Ó°ÏìÁËÏÂÓβî±ðµÄÐźÅͨ·ӰÏìϸ°ûÔöÖ³ºÍÇÖÏ®¡£¡£¡£¡£
6)qRT-PCRÑéÖ¤ÏÂÓλùÒò
×îºó£¬£¬£¬£¬Ñо¿Ö°Ô±¶ÔÌØÒìÐÔµØÔÚZKSCAN1Çýµºóת±äµÄ»ùÒòÓëcircZKSCAN1Çýµºóת±äµÄ»ùÒò¼°¶¼×ª±äµÄ»ùÒò¾ÙÐÐÁËqRT-PCRÑéÖ¤£¬£¬£¬£¬Ð§¹ûÅú×¢£¬£¬£¬£¬ÔÚZKSCAN1Çýµºó£¬£¬£¬£¬Ï¸°û´úлÏà¹Ø»ùÒòȷʵ±¬·¢ÁËÏÔÖø×ª±ä£»£»£»£»£»£»¶øÔÚcircZKSCAN1Çýµºó£¬£¬£¬£¬µòÍöºÍǨáãÏà¹Ø»ùÒò±¬·¢ÏÔÖø×ª±ä£»£»£»£»£»£»COL3A1£¬£¬£¬£¬CDH5£¬£¬£¬£¬MYB£¬£¬£¬£¬PDK1ºÍBCL2ÔÚÁ½ÖÖÇéÐÎ϶¼ÏÔÖø×ª±ä¡£¡£¡£¡£
Ñо¿½áÂÛ
ÔÚ±¾Ñо¿ÖУ¬£¬£¬£¬Ñо¿Ö°Ô±·¢Ã÷£¬£¬£¬£¬ËäÈ»ZKSCAN1ºÍcircRNAÔÚHCCÖж¼±¬·¢ÁËÏÔÖøÏµ÷£¬£¬£¬£¬¶¼ÊÇÓ°Ïìϸ°ûÉú³¤£¬£¬£¬£¬Ç¨áãºÍÇÖÏ®£¬£¬£¬£¬¿ÉÊÇ£¬£¬£¬£¬ËûÃÇÓ°ÏìµÄÏÂÓÎÐźÅͨ·ȴÊǸ÷²»Ïàͬ¡£¡£¡£¡£¸ÃÑо¿ÎªÃ÷È·circRNAºÍÆäĸ»ùÒòÔÚÉúÃüÌåÖеĵ÷¿Ø×÷ÓÃÌṩÁËеÄÒÀ¾Ý¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
Yao Z, Luo J, Hu K£¬£¬£¬£¬et al.£¨2017£©ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinomacell growth, migration and invasion but through different signaling pathways. Mol Oncol. doi: 10.1002/1878-0261.12045
Ч¹ûչʾ
1.»ùÒò±í´ïÖµÃܶÈ
²î±ðÑù±¾¸÷×Ô±í´ïÁ¿´¦Öóͷ£ºóÊýÖµlog10£¨fpkm£©×ö±í´ïÖµÃܶÈͼ£¬£¬£¬£¬¿ÉÒÔ½ÏÁ¿²î±ðÑù±¾¼ä±í´ïÇ÷ÊÆµÄת±ä¡£¡£¡£¡£ÀíÏë״̬Ï£¬£¬£¬£¬¸÷Ñù±¾µÄ±í´ïÃܶÈͼӦÇкÏÕý̬ÂþÑÜ£¬£¬£¬£¬Í¬Ê±ÉúÎïÑ§ÖØ¸´Ñù±¾µÄ±í´ïÇ÷ÊÆÓ¦Ç÷ÓÚÒ»Ö¡£¡£¡£¡£
2.²î±ðcircRNA-hosting gene GO¸»¼¯ÐÔÖù״ͼ
GO¸»¼¯ÐÔÆÊÎöЧ¹ûÖù״ͼ·´Ó¦ÔÚÉúÎïÀú³Ì(biological process)¡¢Ï¸°û×é·Ö (cellularcomponent)ºÍ·Ö×Ó¹¦Ð§(molecular function)¸»¼¯µÄGO termÉϲî±ð»ùÒòµÄ¸öÊýÂþÑÜÇéÐΡ£¡£¡£¡£
3.²î±ðcircRNA-hosting gene KEGG¸»¼¯ÐÔÉ¢µãͼ
ͨ¹ýggplot2¶ÔKEGG¸»¼¯ÆÊÎöЧ¹ûÒÔÉ¢µãͼµÄÐλ¯¾ÙÐÐչʾ£¬£¬£¬£¬ÆäÖкá×ø±êRich factorÌåÏÖλÓÚ¸ÃKEGGµÄ²î±ð»ùÒò¸öÊý/λÓÚ¸ÃKEGGµÄ×Ü»ùÒòÊý£¨Rich factor=S gene number/B gene number£©£¬£¬£¬£¬Rich factorÔ½´ó£¬£¬£¬£¬KEGG¸»¼¯Ë®Æ½ Ô½¸ß¡£¡£¡£¡£×Ý×ø±êÊÇPathway term£¬£¬£¬£¬¼´KEGG´úлͨ·¡£¡£¡£¡£É¢µãͼÖУ¬£¬£¬£¬µãµÄ¾Þϸ´ú±í S gene number Æ¥Åäµ½µ¥¸öKEGGµÄ¾ßÓÐÏÔÖøÐÔ²î±ðµÄ»ùÒòÊý£¬£¬£¬£¬µãµÄÑÕÉ«´ú±í ¸»¼¯ÆÊÎöµÄpÖµ£¬£¬£¬£¬¼´¸»¼¯µÄÏÔÖøÐÔ¡£¡£¡£¡£KEGG¸»¼¯ÆÊÎöÉ¢µãͼÊÇÆ¾Ö¤¸»¼¯µÄÏÔÖø ÐÔ£¨pvalue£©È¡top20µÄPathway term¾ÙÐлæÍ¼¡£¡£¡£¡£
³£¼ûÎÊÌâ
1.CircRNAµÄ³É»·»úÖÆ¶¼ÓÐÄÄЩ£¿£¿
CircRNAµÄ³É»·»úÖÆÓУºÌ×Ë÷Çý¶¯µÄ»·»¯£»£»£»£»£»£»ÄÚº¬×ÓÅä¶ÔÇý¶¯µÄ»·»¯£»£»£»£»£»£»ÄÚº¬×Ó»·»¯£»£»£»£»£»£»RBP»òÒ»À෴ʽÒò×ÓÇý¶¯µÄ»·»¯£»£»£»£»£»£»¿É±ä¼ô½ÓÒýÆðµÄ»·»¯¡£¡£¡£¡£
2.circRNA²âÐòºÍͨË×µÄRNA-seq£¬£¬£¬£¬ÔÚ³éÌátotal RNAʱÓÐÇø±ðÂ𣿣¿
circRNA²âÐò¶Ôtotal RNAµÄÒªÇóÓëͨË×µÄRNA-seqÏàͬ£¬£¬£¬£¬ÒÔÊdzéÌáÒªÁìÒ²Ïàͬ¡£¡£¡£¡£¿ÉÊÇÓÉÓÚcircRNA½¨¿âÐèҪȥ³ýrRNAºÍÏßÐÔRNA£¬£¬£¬£¬ÒÔÊÇÐèÇó´ó×ÚµÄtotal RNA£¬£¬£¬£¬ÐèÌṩ´óÓÚ¼´ÊÇ10 μgµÄtotal RNA¡£¡£¡£¡£
3.circRNAÓëlncRNAµÄÇø±ðÊÇʲô£¿£¿
½á¹¹ÉÏ£¬£¬£¬£¬circRNAûÓÐ×ÔÓɵÄ5’¶ËºÍ3’¶Ë£»£»£»£»£»£»¹¦Ð§ÉÏ£¬£¬£¬£¬ circRNA¹¦Ð§Ñо¿½ÏÁ¿¼òµ¥£¬£¬£¬£¬ÏÖÔÚ¹ØÓÚÆäÊÇ·ñÄܹ»ÏñlncRNAÒ»ÑùÔÚȾɫÌåˮƽ¡¢ÂѰ×ÖÊˮƽÉϾßÓе÷¿Ø×÷Ó㬣¬£¬£¬ÉÐδ¿ÉÖª£¬£¬£¬£¬ÕâЩҲÊÇÏÖÔÚÑо¿µÄÆ«Ïò¡£¡£¡£¡£Æ¾Ö¤ÒÑÓÐÑо¿·¢Ã÷£¬£¬£¬£¬ circRNA¿ÉÒÔʩչº£ÃàЧӦÎü¸½miRNA£¬£¬£¬£¬¿ÉÒÔ×÷Ϊ¾ºÕùÐÔÄÚÔ´RNA¡£¡£¡£¡£
Small RNA²âÐò
Small RNAÖ÷Òª°üÀ¨miRNA¡¢piRNA¡¢tsRNA£¨tRF&tiRNA£©¡¢snRNAºÍsnoRNAµÈ£¬£¬£¬£¬ÆäÖÐmiRNAÑо¿×îΪÆÕ±é£¬£¬£¬£¬ÊÇÒ»À಻¾ßÓÐÂѰױàÂëÄÜÁ¦µÄRNA·Ö×Ó£¬£¬£¬£¬Äܵ÷¿Ø»ùÒò±í´ï£¬£¬£¬£¬ÔÚϸ°ûÉú³¤¡¢·¢ÓýºÍ´úлµÈ»ù´¡ÉúÎïѧÀú³ÌÖж¼ÊÎÑÝ×ÅÖ÷ÒªµÄ½ÇÉ«£¬£¬£¬£¬ÉõÖÁÔÚ°©Ö¢µÈÏà¹Ø¼²²¡ÐγÉÀú³ÌÖÐÒ²Æð×ÅÒªº¦µÄ×÷Óᣡ£¡£¡£
UG»·Çò×éѧЧÀÍÓÅÊÆ
1. ¸ß¶ÈÎÞаÐÔ£º¿ÉÑо¿ÈÎÒ» 17-35 nt Ö®¼äµÄС RNA ·Ö×Ó
2. ¸ß¶È׼ȷÐÔ£º¿É׼ȷµ½µ¥ºËÜÕËáˮƽ£¬£¬£¬£¬ÓÐÀûÓÚÇø·Ö¸ß¶ÈͬԴµÄС RNA ·Ö×ÓºÍÅжÏС RNA µÄ¶à̬ÐÔ
3. ¼ì²â¶¯Á¦Ñ§¹æÄ£¹ã£º¿ÉÔÚÁè¼Ý 6 ¸öÊýÄ¿¼¶¹æÄ£ÄÚʵÏÖ׼ȷµÄÐòÁмì²âºÍ¶¨Á¿ÆÊÎö£¬£¬£¬£¬ÓÐÀûÓÚµÍÆ·Ã²Ð¡ RNA ²î±ð±í´ïµÄÑо¿
4. Êý¾ÝÖÊÁ¿¸ß£ºÉî¶È²âÐò°ü¹ÜÁ˳éÑùËæ»úÐÔ¡¢¿É¿¿ÐÔºÍÖØ¸´ÐÔ£¬£¬£¬£¬Óëʵʱ¶¨Á¿ PCR Ч¹û¾ßÓнϸߵÄÒ»ÖÂÐÔ
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
¶¯Îï¼°ÁÙ´²ÔàÆ÷×éÖ¯/ÄÔ×éÖ¯µÈ |
>20mg |
¶¯Îï¼°ÁÙ´²Æ¤·ô/¹Ç/Ѫ¹Ü/Ö¬·¾×éÖ¯µÈ |
>100mg |
Ö²ÎïҶƬ×éÖ¯/»¨ |
>200mg |
Ö²Îï¸ù/¾¥/¹ûʵ/ÖÖ×Ó |
>500mg |
Ô´úϸ°û/ϸ°ûϵ |
>5×106¸ö |
ÖÐÐÔÁ£Ï¸°û/ÊÈËáÐÔÁ£Ï¸°û/ÊȼîÐÔÁ£Ï¸°û |
>5×107¸ö |
ÍâÃÚÌåÑù±¾ |
>1×108¸ö |
ѪÇå/Ѫ½¬/ÄÔ¼¹Òº/ÊàŦ»ýÒº/ÂÑÅÝÒº |
>2mL |
ϸ°û×÷ÓýÉÏÇåÒº |
>20mL |
ÄòÒº |
>30mL |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ×éÖ¯Ñù±¾½¨ÒéÉúÑÄÔÚRNAlater¡¢RNAHold¡¢RNAProtectµÈÏà¹Ø×éÖ¯ÉúÑÄÒºÖУ¬£¬£¬£¬È»ºó-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Ú ϸ°ûÑù±¾Ê¹ÓÃTRIzolµÈÁѽâÒº³ä·ÖÁѽâÖ®ºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ
Ó¦Óó¡¾°
Ó¦Óó¡¾°1£ºÍâÃÚÌå
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢¶¯Îï/ÊÞÒ½Ñо¿µÈí§ÒâÑо¿Æ«Ïò
MicroRNA£¨miRNA£©ÊÇÒ»Àà·Ç±àÂëRNA£¬£¬£¬£¬Äܹ»µ÷ÀíһϵÁÐÆÕ±éµÄÉúÎïÀú³Ì¡£¡£¡£¡£³ýÁËÔÚϸ°ûÄÚʩչ×÷ÓÃÍ⣬£¬£¬£¬×î½üÑо¿»¹ÏÔʾmiRNAÔÚϸ°ûÍâÃÚÌåÖÐÉøÍ¸£¬£¬£¬£¬´Ó¶øÔÊÐíÆä×ªÒÆÖÁ½ü¶Ë»òÔ¶¶ËµÄϸ°û½ø¶øµ÷Àí»ùÒò±í´ï¡£¡£¡£¡£ÍâÃÚÌå´ú±í×ÅÓÐÏ£Íû¿ÉÒÔ´ÓÖÐÊèÉ¢miRNAµÄÄÉÃ×ÖÊÁÏ£¬£¬£¬£¬ÓÐʩչÖÎÁÆ×÷ÓõÄDZÁ¦¡£¡£¡£¡£
Ó¦Óó¡¾°2£º´óÑù±¾Ñо¿
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§£¬£¬£¬£¬¼²²¡±ê¼ÇÎïÍÚ¾òÓëÅжÏ
miRNAÊÇÒ»ÖÖÎȹÌÐÔÇ¿ÖØ¸´ÐÔºÃÒ×ÓÚ¼ì²âµÄ·Ç±àÂëRNA£¬£¬£¬£¬ÔÚÌåÒºÑù±¾¼°×éÖ¯Ñù±¾ÖÐÆ·Ã²¸ß£¬£¬£¬£¬ÔÚÁÙ´²ÉϾ߱¸³ÉÎªÌØÒìÐÔǿѸËٶȵÄÉúÎï±ê¼ÇÎbiomarker£©µÄDZÄÜ¡£¡£¡£¡£ÀýÈçÍâÃÚÌå»òÌåÒºÑù±¾ÖУ¬£¬£¬£¬Áè¼Ý70%µÄRNAΪmiRNA£¬£¬£¬£¬ÅäºÏ»Ø¹éºÍÖÖÖÖ»úеѧϰ½¨Ä££¬£¬£¬£¬¿ÉÍÚ¾ò¸ßѸËٶȵÄDZÔÚÉúÎï±ê¼ÇÎï¡£¡£¡£¡£
Ó¦Óó¡¾°3£ºÒÖÖÆ·Òë/¼¤»î·Òë
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§Óë·Ö×ÓÉúÎïѧ¡¢¶¯Ö²ÎïÑо¿µÈí§ÒâÑо¿Æ«Ïò
miRNA¿Éͨ¹ýÒÖÖÆºËÌÇÌåµÄ×é×°À´×è¶Ï·ÒëÆðʼ£¬£¬£¬£¬½ø¶øÆðµ½¶Ô·ÒëÀú³ÌµÄÒÖÖÆ×÷Óᣡ£¡£¡£miRNAµÄÒÖÖÆ×÷ÓÃÐèÒª°ÐmRNA¾ßÓÐm7Gñ×Ó½á×é³ÉΪ֧³ÖÕâÒ»ÀíÂÛµÄÖ÷ÒªÒÀ¾Ý£¬£¬£¬£¬ÓÉ´Ë¿ÉÒÔÍÆ¶Ï miRISC¿ÉÄÜͨ¹ý¶Ô·ÒëÆðʼ¸´ºÏÎïÐγÉÒÖÖÆ¶øÊ©Õ¹×÷Ó㻣»£»£»£»£»Ago2ÖÐÐĽṹÓò¾ßÓÐÁ¬Ïµm7Gñ×ӵĻîÐÔ£¬£¬£¬£¬Ago2ͨ¹ý ¶ÔmiRNAÕÐļ°ÐmRNAµÄ 3' UTR£¬£¬£¬£¬´Ó¶øÓëÆðʼ¸´ºÏÎïeIF4E/G¾ºÕùÐÔÁ¬Ïµm7Gñ×Ó£¬£¬£¬£¬×îÖÕʩչ¶Ô·ÒëÆðʼ¸´ºÏÎïµÄÒÖÖÆ×÷Óᣡ£¡£¡£ÏÖʵÉÏmiRNA¾ßÓÐË«ÖØ¹¦Ð§£¬£¬£¬£¬µ±Î»ÓÚ°û½¬Ê±¿ÉÒÖÖÆ»ùÒò±í´ï£¬£¬£¬£¬µ±Î»ÓÚϸ°ûºËÄڿɼ¤»î»ùÒòµÄת¼¡£¡£¡£¡£ºËÄÚmiRNA¿Éͨ¹ýÁ¬ÏµÔöÇ¿×Ó£¬£¬£¬£¬¸Ä±äÔöÇ¿×ÓµÄȾɫÖÊ״̬£¬£¬£¬£¬´Ó¶ø¼¤»î»ùÒòµÄת¼±í´ï¡£¡£¡£¡£
Ó¦Óó¡¾°4£ºÓ뵥ϸ°û²âÐòÁªºÏÆÊÎö
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§Óë·Ö×ÓÉúÎïѧ¡¢¶¯Ö²ÎïÑо¿µÈí§ÒâÑо¿Æ«Ïò
miRNAÓ뵥ϸ°ûÁªºÏÆÊÎö£¬£¬£¬£¬Ö÷Ҫͨ¹ýÁ½ÖÖÒªÁì¡£¡£¡£¡£µÚÒ»ÖÖÊÇͨ¹ý¶ÔmiRNAµÄ°Ð»ùÒòËù¶ÔÓ¦µÄ»ùÒò¼¯ÔÚµ¥Ï¸°û²âÐòÖÐÓÃAddModuleScore´ò·ÖÄ£¿£¿éʵÏÖ¡£¡£¡£¡£µÚ¶þÖÖ¾ÍÊÇÒýÈëÁËRIPºÍCLIPÊý¾Ý¿âÀ´¾ÙÐкóÆÚУÕý¡£¡£¡£¡£¼´¼ä½Ó´ò·ÖºÍÖ±½Ó´ò·ÖÁ½ÖÖÒªÁì¡£¡£¡£¡£
ͨ¹ýmiRNAÓ뵥ϸ°ûÁªºÏ£¬£¬£¬£¬Äܹ»Ëø¶¨Í¨Â·¸»¼¯½Ï¸ßµÄϸ°ûÑÇȺ£¬£¬£¬£¬²¢ºÍmiRNA½¨ÉèÆðÖ±½Óµ÷¿ØºÍ¼ä½Óµ÷¿ØÁ½ÖÖ·½·¨¡£¡£¡£¡£
Ó¦Óó¡¾°5£ºceRNAµ÷¿Ø»úÖÆ
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§Óë·Ö×ÓÉúÎïѧ¡¢¶¯Ö²ÎïÑо¿µÈí§ÒâÑо¿Æ«Ïò
ceRNAÈ«³Æcompeting endogenous RNA£¬£¬£¬£¬ÊÇÒ»ÖÖÄܹ»¾ºÕùÁ¬ÏµRNAµÄ×÷ÓÃÔª¼þ¡£¡£¡£¡£Í¨³£lncRNAºÍcircRNA»á¾ºÕùÁ¬ÏµmiRNA£¬£¬£¬£¬ÎÒÃÇÒ»Ñùƽ³£°ÑlncRNAºÍcircRNA¿ÉÒÔ³Æ×÷ceRNA¡£¡£¡£¡£ceRNAµ÷¿ØÍøÂçÈ«³ÆceRNAregulation network£¬£¬£¬£¬Ö¸µÄÊÇÓÐceRNA¼ÓÈëµÄÕû¸öµ÷¿ØÍøÂçcascade¡£¡£¡£¡£¶øceRNAÆÊÎöÖ¸µÄÊǶÔÕû¸öceRNAµ÷¿ØÍøÂç¾ÙÐÐÆÊÎö¡£¡£¡£¡£Ò»Ñùƽ³£ÓÐcircRNA-miRNA-mRNAÆÊÎö»òlncRNA-miRNA-mRNAÆÊÎö¡£¡£¡£¡£
Ó¦Óó¡¾°6£ºÖ²ÎïmiRNAÓë½µ½â×éÁªºÏ
ÊÊÓùæÄ££ºÖ²Î²¡¿¹ºµµÈ¿¹ÄæÑо¿¡¢Ö²ÎïÒÅ´«ÓýÖÖ¡¢Ö²Îï·¢ÓýѧµÈí§ÒâÑо¿Æ«Ïò
ͨ¹ý½µ½â×é²âÐòºÍmiRNA²âÐòµÄÁªºÏÓ¦Ó㬣¬£¬£¬Ñо¿Õß²»µ«¿ÉÒÔϵͳÅж϶àݪֲÎïÖÐmiRNAµ÷¿ØµÄ°Ð»ùÒò£¬£¬£¬£¬»¹¿ÉÒÔ̽ÌÖ¶àÖÖmiRNA¼°Æä°Ð»ùÒò¶ÔÖ²Îï²î±ð´¦Öóͷ£µÄ²î±ðÐÔ±í´ï£¬£¬£¬£¬Ö¤ÊµÄ³Ð©miRNAµÄ°Ð»ùÒòÔÚÖ²ÎïÉú³¤·¢ÓýÀú³ÌÖеÄÖ÷Òª×÷Óᣡ£¡£¡£
ÏîÄ¿ÎÄÕÂ
¡¾1¡¿Su T, et al. Bone Marrow Mesenchymal Stem Cells-Derived Exosomal MiR-29b-3p Regulates Aging-Associated Insulin Resistance. ACS Nano. 2019 Feb 26;13(2):2450-2462. PMID: 30715852.
¡¾2¡¿Ma L, et al. Nanotopography Sequentially Mediates Human Mesenchymal Stem Cell-Derived Small Extracellular Vesicles for Enhancing Osteogenesis. ACS Nano. 2022 Jan 25;16(1):415-430. PMID: 34935354.
Ч¹ûչʾ
1.²î±ðmiRNAÉÏϵ÷ͳ¼ÆÆÊÎö
²î±ð»ùÒòÉÏϵ÷ƵÊýͳ¼ÆÓÃÓÚÅжϲî±ðʵÑéÌõ¼þϲî±ð±í´ïmiRNAµÄ¸öÊý¡£¡£¡£¡£ÆäÖкá×ø±êÌåÏÖ½ÏÁ¿×éÐÅÏ¢£¬£¬£¬£¬×Ý×ø±êÌåÏÖÉÏϵ÷miRNAµÄÊýÄ¿£¬£¬£¬£¬ºìÉ«´ú±íÉϵ÷miRNA£¬£¬£¬£¬À¶É«´ú±íϵ÷miRNA£¬£¬£¬£¬ÆäÖÐÊý×Ö´ú±íÉÏϵ÷miRNAµÄÊýÄ¿¡£¡£¡£¡£
2.²î±ðmiRNA¾ÛÀàÆÊÎö
²î±ðmiRNA¾ÛÀàÆÊÎöÓÃÓÚÅжÏmiRNAÔÚ²î±ðʵÑéÌõ¼þϵ÷¿ØµÄ¾ÛÀàģʽ¡£¡£¡£¡£Æ¾Ö¤ÑùÆ·miRNA±í´ïÆ×µÄÏà½üˮƽ£¬£¬£¬£¬½«miRNA¾ÙÐоÛÀàÆÊÎö£¬£¬£¬£¬Ö±¹ÛµØÕ¹Ê¾miRNAÔÚ²î±ðÑùÆ·£¨»òÊDzî±ð´¦Öóͷ££©Öеıí´ïÇéÐΣ¬£¬£¬£¬ÓÉ´Ë»ñÈ¡ÉúÎïѧÏà¹ØÐÅÏ¢¡£¡£¡£¡£²î±ðµÄÑÕÉ«ÌåÏÖ²î±ðµÄmiRNA±í´ïˮƽ£¬£¬£¬£¬ÑÕÉ«ÓÉÀ¶É«¾Óɰ×É«ÖÁºìÉ«ÌåÏÖ±í´ïÁ¿´ÓµÍµ½¸ß¡£¡£¡£¡£ºìÉ«ÌåÏָ߱í´ï»ùÒò£¬£¬£¬£¬ÉîÀ¶É«ÌåÏֵͱí´ï»ùÒò¡£¡£¡£¡£

3.²î±ðmiRNAΤ¶÷ͼ
ͨ¹ý²î±ð½ÏÁ¿×éÖ®¼ä²î±ð»ùÒòΤ¶÷ͼ¿ÉÒÔÖ±¹ÛµØÏÔʾ³ö²î±ð½ÏÁ¿×éÖ®¼äÅäºÏµÄºÍÌØÓеIJî±ð±í´ïmiRNAµÄ¸öÊý£¬£¬£¬£¬²î±ð»ùÒòΤ¶÷ͼ¾ßÓÐÏÔ×ŵÄÉúÎïѧÒâÒ壬£¬£¬£¬ºÃ±ÈÊÇÏàͬ±ÈÕÕ²î±ð´¦Öóͷ£µÄʵÑéÉè¼ÆÇéÐΣ¬£¬£¬£¬¿ÉÒÔ½«²î±ð´¦Öóͷ£ÏµIJî±ð»ùÒò¾ÙÐнÏÁ¿¡£¡£¡£¡£
4.GO¸»¼¯ÐÔÖù״ͼ
miRNA°Ð»ùÒòµÄGO¸»¼¯Öù״ͼ£ºÓÃÓÚ·´Ó¦ÔÚÉúÎïÀú³Ì(biological process)¡¢Ï¸°û×é·Ö(cellular component)ºÍ·Ö×Ó¹¦Ð§(molecular function)¸»¼¯µÄGO termÉϲî±ð»ùÒòµÄ¸öÊýÂþÑÜÇéÐΡ£¡£¡£¡£
5.GO¸»¼¯ÐÔÉ¢µãͼ
¶Ô²î±ðmiRNA¾ÙÐÐGO¸»¼¯ÆÊÎö²¢ÒÔÉ¢µãͼչʾ£¬£¬£¬£¬Rich factorÌåÏÖλÓÚ¸ÃGOµÄ²î±ð»ùÒò¸öÊý/λÓÚ¸ÃGOµÄ×Ü»ùÒòÊý£¬£¬£¬£¬PֵԽС£¬£¬£¬£¬GO¸»¼¯Ë®Æ½Ô½¸ß¡£¡£¡£¡£
³£¼ûÎÊÌâ
1.miRNAÃüÃû¹æÔòÊÇÔõÑùµÄ£¿£¿
¹ØÓÚmiRNAÃüÃû£¬£¬£¬£¬ÊÇÆ¾Ö¤miRBaseµÄÃüÃû¹æÔò£ºÎïÖÖÀ¶¡Ãû3×ÖĸËõд-miR/MIR-±àºÅ£¨Ö²Î£¬£¬£¬£¬miRÌåÏÖµÄÊÇmicroRNA³ÉÊìÌ壬£¬£¬£¬Ö²ÎïµÄǰÌåʹÓÃMIR¡£¡£¡£¡£°Ý¼ûmiRBase¹ÙÍø:ÏÖÔÚÒѾ²»ÔÙʹÓÃ*À´±ê¼ÇmicroRNAÓëÆä·¢¼ÐǰÌ廥²¹Åä¶ÔλÖõĻ¥²¹ÐòÁУ¬£¬£¬£¬¶øÊÇʹÓÓ-3p”Óë“-5p”×÷ÎªÇø·ÖÕâÁ½ÌõÐòÁеĺó×ºÌæ»»¾ÉµÄµÄÃüÃû·¨¡£¡£¡£¡£Ïêϸ²Î¿¼17.0°æ±¾³öÀ´Ê±£¬£¬£¬£¬miRbaseÊý¾Ý¿âµÄblogÎÄÕ£ºhttp://www.mirbase.org/blog/2011/04/mirbase-17-released/
2.ÔõÑùɸѡ²î±ð»ùÒò£¿£¿
¿ÉÒÔÔÚɸѡµÄʱ¼ä¿ÉÄÜÐèÒª²Î¿¼¸Ã²ÎÊý£¬£¬£¬£¬Ò»Ñùƽ³£ÈôÊÇרעÓÚ·¢Ã÷£¬£¬£¬£¬ÄÇôËùÓб£´æ£¬£¬£¬£¬ÈôÊÇרעÓÚ²î±ð±í´ï£¬£¬£¬£¬¿ÉÒÔ½ö±£´æhighºÍmiddle¿½±´µÄ¡£¡£¡£¡£log2(Treat/Control)>0ÌåÏÖÉϵ÷£¬£¬£¬£¬<0ÌåÏÖϵ÷£¬£¬£¬£¬>1ÌåÏÖÉϵ÷2±¶£¬£¬£¬£¬<-1ÌåÏÖϵ÷2±¶¡£¡£¡£¡£×î¼òÆÓµÄ½ÏÁ¿¾Þϸ£¬£¬£¬£¬¾ÍÊÇTreat-Control£¨¿´´óÓÚÕÕ¾ÉСÓÚ0£©£¬£¬£¬£¬»òÕßTreat/Control£¨¿´´óÓÚÕÕ¾ÉСÓÚ1£©£¬£¬£¬£¬¸üÓпɶÁÐԵľÍÊÇlog2(Treat/Control)£¨>0ÌåÏÖÉϵ÷£¬£¬£¬£¬<0ÌåÏÖϵ÷£¬£¬£¬£¬>1ÌåÏÖÉϵ÷2±¶£¬£¬£¬£¬<-1ÌåÏÖϵ÷2±¶£©¸ºÏà¹Ø¡¢²î±ðÏÔÖøÐÔpvalueÖµ¡¢foldchage¡¢×îµÍ¿½±´Öµ¡£¡£¡£¡£
ȫת¼×é²âÐò
¶Ô×éÖ¯»òϸ°ûÔÚijһʱ¿Ì»ò´¦Öóͷ£Ìõ¼þÏÂת¼³öÀ´µÄËùÓÐRNA¾ÙÐвâÐòÆÊÎö£¬£¬£¬£¬È«×ªÂ¼×éµÄÑо¿ÖаüÀ¨¶ÔmRNA¡¢lncRNA¡¢circRNA¡¢miRNA¾ÙÐÐÆÊÎö£¬£¬£¬£¬²¢Á¬Ïµ¶àÖÖRNAÐÅϢ̽Ë÷Ï໥֮¼äDZÔڵĵ÷¿ØÍøÂç¡£¡£¡£¡£
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
¶¯Îï¼°ÁÙ´²ÔàÆ÷×éÖ¯/ÄÔ×éÖ¯µÈ |
>20mg |
¶¯Îï¼°ÁÙ´²Æ¤·ô/¹Ç/Ѫ¹Ü/Ö¬·¾×éÖ¯µÈ |
>100mg |
Ö²ÎïҶƬ×éÖ¯/»¨ |
>200mg |
Ö²Îï¸ù/¾¥/¹ûʵ/ÖÖ×Ó |
>500mg |
Ô´úϸ°û/ϸ°ûϵ |
>5×106¸ö |
ÖÐÐÔÁ£Ï¸°û/ÊÈËáÐÔÁ£Ï¸°û/ÊȼîÐÔÁ£Ï¸°û |
>5×107¸ö |
ÍâÃÚÌåÑù±¾ |
>1×108¸ö |
ѪÇå/Ѫ½¬/ÄÔ¼¹Òº/ÊàŦ»ýÒº/ÂÑÅÝÒº |
>2mL |
ϸ°û×÷ÓýÉÏÇåÒº |
>20mL |
ÄòÒº |
>30mL |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ×éÖ¯Ñù±¾½¨ÒéÉúÑÄÔÚRNAlater¡¢RNAHold¡¢RNAProtectµÈÏà¹Ø×éÖ¯ÉúÑÄÒºÖУ¬£¬£¬£¬È»ºó-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Ú ϸ°ûÑù±¾Ê¹ÓÃTRIzolµÈÁѽâÒº³ä·ÖÁѽâÖ®ºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ¡£¡£¡£¡£
Ó¦Óó¡¾°
Ó¦Óó¡¾°1£º½á¹¹·Ö×ÓÕÐļ½¹µãÂѰ×ÓëºËËá
ÊÊÓùæÄ££º»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧµÈí§ÒâÑо¿Æ«Ïò
lncRNAºÍcircRNAÓÐʱ¼ä»á×÷ΪһÖÖÌØÊâµÄRNA·Ö×Ó£¬£¬£¬£¬ÐγÉÂѰ×-ÂѰ׸´ºÏÎï»òÂѰ×-ºËËáµÄ¹Ç¼Ü·Ö×Ó£¬£¬£¬£¬¶ÔÏÂÓηÖ×ÓÐÐʹһϵÁе÷¿Ø×÷Óᣡ£¡£¡£È粿·ÖcircRNA»áÕÐļһЩ·ºËØ»¯Ã¸¶ÔÏÂÓεÄÂѰ×ÐÐʹ½µ½â¹¦Ð§£¬£¬£¬£¬»òÕß²¿·ÖlncRNA»áÕÐļһЩת¼Òò×ÓÓëÄ¿µÄ»ùÒòµÄÆô¶¯×ÓÇøÓòÁ¬Ïµ¼¤»îÏÂÓεĻùÒò±í´ïµÈ¡£¡£¡£¡£
Ó¦Óó¡¾°2£ºÍâÃÚÌå
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§µÈí§ÒâÑо¿Æ«Ïò
lncRNAÔÚÍâÃÚÌåÖÐÓÉÓÚÒÔË鯬ÐÎʽ±£´æ£¬£¬£¬£¬ÕâÖÖËæ»úƬ¶Ï²»µ«µ¹ÔËÓÚ¼ì²â£¬£¬£¬£¬²¢Çҽϵ͵ÄŨ¶ÈºÍ½Ï²îµÄÖØ¸´ÐÔ£¬£¬£¬£¬Ê¹µÃlncRNA²¢²»ÊÇÍâÃÚÌåÑо¿µÄÈÈÃÅ·Ö×ÓÖ®Ò»¡£¡£¡£¡£¿ÉÊÇcircRNAÓÉÓÚÆäÎȹÌÐÔ£¬£¬£¬£¬³ýÁË´ÓÌåÒºÑù±¾ÍâÃÚÌåÖÐÊèÉ¢circRNA¿É×÷Ϊ¼²²¡±ê¼ÇÎïÍ⣬£¬£¬£¬»¹ÄÜÓÃÓÚºóÆÚµÄÍâÃÚÌåÖÎÁƵÈÁìÓò£¬£¬£¬£¬ÊǺóceRNAʱ´úÖнÏΪÈÈÃŵÄcircRNAϸ·ÖÑо¿ÁìÓòÆ«ÏòÖ®Ò»¡£¡£¡£¡£ÆäÖÐÒ»¸öÆ«ÏòÊǼ²²¡±ê¼ÇÎ£¬£¬£¬Ò»Ñùƽ³£ÒÔ´óÑù±¾ÐÐÁÐÑо¿¾Ó¶à¡£¡£¡£¡£Ò»ÖÖÊǺóÆÚת»¯¼°»úÖÆÑо¿Æ«Ïò£¬£¬£¬£¬°üÀ¨ÍâÃÚÌåÊÜÌåϸ°û·Ö×Ó»úÖÆÑо¿ÒÔ¼°¼²²¡ÖÎÁÆµÈÆ«Ïò¡£¡£¡£¡£
Ó¦Óó¡¾°3£º·Òë¶àëÄ
ÊÊÓùæÄ££ºÁÙ´²Óëת»¯Ò½Ñ§¡¢»ù´¡Ò½Ñ§¡¢ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧµÈí§ÒâÑо¿Æ«Ïò
circRNAÉÏÓÐÒ»¶Îδ·ÒëµÄRNAÐòÁУ¬£¬£¬£¬³ÆÎªIRES£¬£¬£¬£¬Ëü¿ÉÒÔÕÛµþ³ÉÀàËÆÓÚÆðʼtRNAµÄ½á¹¹£¬£¬£¬£¬²¢ÕÐļ¸ü¶àµÄºËÌÇÌå¡£¡£¡£¡£Õý³£ÇéÐÎÏ£¬£¬£¬£¬IRES²»ÓëeIFÁ¬Ïµ£¬£¬£¬£¬¶øÊÇÓëÒ»Àà³ÆÎªITAFµÄÂѰ×ÖÊÁ¬Ïµ¡£¡£¡£¡£ITAFµÄ×÷ÓÃÊǽ«ºËÌÇÌåÕÙļµ½circRNAµÄÄÚ²¿½á¹¹£¬£¬£¬£¬ÒÔÆô¶¯ÂѰ×ÖÊ·Òë¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬»¹¿ÉÄܱ£´æIRESÔöÇ¿×Ó£¬£¬£¬£¬ÀàËÆÓÚcirc-ZNF609µÄUTRÔª¼þ¡£¡£¡£¡£Ò²ÓÐÑо¿Í¨¹ý·Òë×é²âÐòÓëת¼×é²âÐò£¬£¬£¬£¬·¢Ã÷Á˷DZàÂëRNA LINC-PINTÐγɻ·×´RNAºó¿É±»·ÒëÐÎÀÖ³ÉÄܶàëÄ¡£¡£¡£¡£
Ó¦Óó¡¾°4£ºceRNAµ÷¿Ø»úÖÆ
ceRNAÈ«³Æcompeting endogenous RNA£¬£¬£¬£¬ÊÇÒ»ÖÖÄܹ»¾ºÕùÁ¬ÏµRNAµÄ×÷ÓÃÔª¼þ¡£¡£¡£¡£Í¨³£lncRNAºÍcircRNA»á¾ºÕùÁ¬ÏµmiRNA£¬£¬£¬£¬ÎÒÃÇÒ»Ñùƽ³£°ÑlncRNAºÍcircRNA¿ÉÒÔ³Æ×÷ceRNA¡£¡£¡£¡£ceRNAµ÷¿ØÍøÂçÈ«³ÆceRNA regulation network£¬£¬£¬£¬Ö¸µÄÊÇÓÐceRNA¼ÓÈëµÄÕû¸öµ÷¿ØÍøÂçcascade¡£¡£¡£¡£¶øceRNAÆÊÎöÖ¸µÄÊǶÔÕû¸öceRNAµ÷¿ØÍøÂç¾ÙÐÐÆÊÎö¡£¡£¡£¡£Ò»Ñùƽ³£ÓÐcircRNA-miRNA-mRNAÆÊÎö»òlncRNA-miRNA-mRNAÆÊÎö¡£¡£¡£¡£
°¸Àýչʾ
circular RNA(HRCR)°Ð±êÁ¬ÏµmiR-223±£»£»£»£»£»£»¤ÐÄÔàÃâÊÜÐļ¡·ÊºñºÍÐÄÔàË¥½ß
±¾Ñо¿ÖÐ×÷ÕßÊ×ÏÈͨ¹ýmiRNA»ùÒòоƬÆÊÎö¡¢Northern blot¡¢RT-PCRµÈÊÖÒÕÊֶη¢Ã÷£¬£¬£¬£¬ISO´¦Öóͷ£14Ììºó£¬£¬£¬£¬miRNA-223µÄ±í´ïÁ¿ÏÔÖøÉϵ÷£¬£¬£¬£¬²¢ÇÒÔÚ»¼ÓÐÐÄÔà·ÊºñºÍÐÄÔàË¥½ßµÄÈ˺ÍСÊóÐÄÔàÖÐmiRNA-223µÄ±í´ïÁ¿Ò²ÓÐÏÔ×ŵÄÉϵ÷£¬£¬£¬£¬ÆðÔ´µÃ³ö½áÂÛ£ºmiRNA-223¼ÓÈëµ÷¿ØÐļ¡·ÊºñºÍÐÄÔàË¥½ß¡£¡£¡£¡£½ÓÏÂÀ´×÷ÕßʹÓÃmiR-223¹ý±í´ïת»ùÒòСÊóÒÔ¼°miR-223»ùÒòÇóýת»ùÒòСÊó½øÒ»²½ÑéÖ¤±íÐÍ£¬£¬£¬£¬Ð§¹û·¢Ã÷miR-223¹ý±í´ïСÊó³ÉÄêºó·ºÆðÏÔ×ŵÄÐļ¡·ÊºñºÍÐÄÔàË¥½ßÖ¢×´£¬£¬£¬£¬¶ømiR-223»ùÒòÇóýСÊó±íÐÍÏà·´£¬£¬£¬£¬½øÒ»²½Ö¤ÊµÔÚ»îÌåÄÚ£¬£¬£¬£¬miR-223¿ÉÒÔÓÕµ¼Ðļ¡·ÊºñºÍÐÄÔàË¥½ß¡£¡£¡£¡£
½ÓÏÂÀ´×÷Õß½øÒ»²½Ñо¿miR-223¶ÔÐļ¡Ï¸°ûµÄÓ°Ï죬£¬£¬£¬Ð§¹û·¢Ã÷miR-223¹ý±í´ïϸ°ûÖзºÆðÏÔ×ŵÄÐļ¡·Ê´ó·´Ó¦£¬£¬£¬£¬¶ømiR-223Çóýϸ°ûÖУ¬£¬£¬£¬ISO´¦Öóͷ£ÒýÆðµÄÐļ¡·Ê´ó·´Ó¦ÏÔ×ű»ÆÆË𣬣¬£¬£¬ËµÃ÷miR-223¹ý±í´ï»áÔö½øÐļ¡·Êºñ£¬£¬£¬£¬¶ømiR-223»ùÒòÇóý»á×è¶ÏÐļ¡·Êºñ¡£¡£¡£¡£
ΪÁ˽øÒ»²½Ñо¿miR-223µ÷¿ØÐļ¡·ÊºñºÍÐÄÔàË¥½ßµÄ·Ö×Ó»úÖÆ£¬£¬£¬£¬×÷ÕßɸѡÁËһЩ¼ÓÈëµ÷¿ØÐļ¡·ÊºñµÄ»ùÒò×÷ΪmiR-223µÄ°Ð±êºòÑ¡»ùÒò£¬£¬£¬£¬È»ºóͨ¹ýwestern blotÆÊÎömiR-223¹ý±í´ïºÍȱʧͻ±äÌåÖÐÉϵ÷ÒÔ¼°Ïµ÷µÄ»ùÒò£¬£¬£¬£¬Ð§¹û·¢Ã÷miR-223¿ÉÒÔÏÔÖøÒÖÖÆARCµÄ±í´ï£¬£¬£¬£¬¶øÇ°ÈËÒѾÓÐÑо¿±¨µÀARC¼ÓÈëµ÷¿ØÐļ¡·ÊºñºÍϸ°ûµòÍö£¬£¬£¬£¬ÒÔÊÇÆðÔ´ÍÆ¶ÏARC¿ÉÄÜÊÇmiR-223ÏÂÓεİбêλµã¡£¡£¡£¡£

CircRNAºÍmiRNAµÄ»¥×÷ÊÇÏÖÔÚÑо¿µÄÒ»¸öÈÈÃÅ»°Ì⣬£¬£¬£¬ÎªÁ˽øÒ»²½Ñо¿ÊÇ·ñÓÐCircRNA¼ÓÈëµ÷¿ØmiR-223µÄ±í´ï£¬£¬£¬£¬×÷Õß´ÓCircRNAÊý¾Ý¿âÖÐËæ»úɸѡ³ö100¸öCircRNA£¬£¬£¬£¬Í¨¹ýqRT-PCRÑé֤ɸѡµ½36¸öCircRNA£¬£¬£¬£¬È»ºóͨ¹ýNorthern blotɸѡµ½Ò»¸öÌØÒìÐÔ±í´ïµÄCircRNA: mm9-circ-012559(HRCR)¡£¡£¡£¡£
È»ºó×÷Õßͨ¹ýRNAhybridÆÊÎö·¢Ã÷HRCR°üÀ¨6¸öCircRNAµÄ°Ð±êÁ¬ÏµÎ»µã£¬£¬£¬£¬ÆðÔ´Åú×¢HRCR¿ÉÒÔºÍmiR-223Á¬Ïµ¡£¡£¡£¡£½ÓÏÂÀ´×÷Õßͨ¹ýÉúÎïËØ±ê¼Ç£¬£¬£¬£¬qRT-PCR£¬£¬£¬£¬Northern bolt£¬£¬£¬£¬pull down assay¡¢Ó«¹âÔλÔÓ½»£¨FISH£©µÈÊÖÒÕÊֶΣ¬£¬£¬£¬´ÓÕýÏòÒÔ¼°·´ÏòÁ½¸ö½Ç¶È»®·ÖÑéÖ¤HRCRºÍmiR-223Ö®¼äµÄ»¥×÷¹ØÏµ£¬£¬£¬£¬Ð§¹û·¢Ã÷miR-223ºÍHRCRÔÚϸ°ûÖÊÖб£´æ¹²¶¨Î»Õ÷Ï󣬣¬£¬£¬HRCR¿ÉÒÔÖ±½ÓÁ¬Ïµµ½miR-223ÉÏ¡£¡£¡£¡£

HRCRºÍmiR-223±£´æ»¥×÷£¬£¬£¬£¬¶ømiR-223¿ÉÒÔͨ¹ýµ÷¿ØÏÂÓÎARCµÄ±í´ï£¬£¬£¬£¬½ø¶øµ÷¿ØÐļ¡·ÊºñºÍÐÄÔàË¥½ß£¬£¬£¬£¬ÎªÁ˽øÒ»²½Ñо¿HRCR¶ÔARC±í´ïµÄÓ°Ï죬£¬£¬£¬×÷Õß¹¹½¨ÁËHRCR¹ý±í´ïÔØÌåºÍ»ùÒòÇóýÍ»±äÌ壬£¬£¬£¬Ð§¹û·¢Ã÷HRCR¹ý±í´ïÔØÌåÖУ¬£¬£¬£¬ARCµÄ±í´ïÁ¿ºÍ»îÐÔÏÔÖøÔöÌí£¬£¬£¬£¬HRCRÇóýÍ»±äÌåÖУ¬£¬£¬£¬ARCµÄ±í´ïÁ¿ºÍ»îÐÔÏÔÖø½µµÍ£¬£¬£¬£¬²¢ÇÒHRCR¿ÉÒÔÏû³ýmiR-223¶ÔARC±í´ïµÄÒÖÖÆ×÷Ó㬣¬£¬£¬ËµÃ÷HRCR¿ÉÒÔͨ¹ýµ÷¿ØmiR-223ÒÔ¼°ARCµÄ±í´ï£¬£¬£¬£¬½ø¶øµ÷¿ØÐļ¡·Êºñ¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
Wang K, Long B, Liu F, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.[J]. European Heart Journal, 2016, 37(33):2602-2611.
³£¼ûÎÊÌâ
1.ȫת¼×é²âÐòΪʲôÐèÒª¹¹½¨Á½¸öÎÄ¿â
ȫת¼×é²âÐòÐèÒª¹¹½¨2¸ö²âÐòÎĿ⣬£¬£¬£¬Ò»¸öСRNAÎÄ¿âºÍÒ»¸öÈ¥³ýºËÌÇÌåRNAµÄÁ´ÌØÒìÐÔÎĿ⣬£¬£¬£¬È»ºó»®·ÖÉÏ»ú²âÐò¡£¡£¡£¡£Ð¡RNA³¤¶È½Ï¶Ì£¬£¬£¬£¬Ò»Ñùƽ³£Ð¡ÓÚ50nt£¬£¬£¬£¬½ÓÄɲâÐòÕ½ÂÔΪ50SE¡£¡£¡£¡£ÆäËûÈýÀàRNAÐòÁÐÒ»Ñùƽ³£´óÓÚ200£¬£¬£¬£¬Í¨³£ÔÚ1000ÒÔÉÏ£¬£¬£¬£¬×î¸ß¿É´ï¼¸Íò£¬£¬£¬£¬Í¨¹ýƬ¶Ï»¯¹¹½¨150PE²âÐòÎĿ⡣¡£¡£¡£×îºóСRNAÎÄ¿â¿ÉÒÔ»ñµÃmiRNAÐòÁÐÐÅÏ¢£¬£¬£¬£¬È¥ºËÌÇÌåµÄÁ´ÌØÒìÐÔÎÄ¿â¿ÉÒÔ»ñµÃmRNA¡¢lncRNAºÍcircRNAµÄÐòÁÐÐÅÏ¢¡£¡£¡£¡£
2.ʲôÊÇceRNAµ÷¿ØÍøÂ磨ceRNA networks£©¡£¡£¡£¡£
ÕâЩ·Ç±àÂëRNAÈçlncRNAºÍcircRNAµÈ»á¾ºÕùÁ¬ÏµmiRNA£¬£¬£¬£¬µ¼ÖÂmiRNAµ÷¿ØµÄ°Ð»ùÒò±¬·¢×ª±ä£¬£¬£¬£¬×îÖÕÌåÏÖÔÚÂѰ׵ıí´ïˮƽÉÏ£¬£¬£¬£¬¶ømiRNA´¦ÓÚceRNAµ÷¿ØÍøÂçÖеĽ¹µãְλ¡£¡£¡£¡£ÈçÏÂͼ
ÔºËת¼×é
»ùÓÚ¸ßͨÁ¿²âÐòƽ̨£¬£¬£¬£¬¹¹½¨Á´ÌØÒìÐÔÎĿ⣬£¬£¬£¬Ñо¿ÔºËÉúÎïÔÚij¸öʱÆÚ»òÕßÔÚijÖÖÇéÐÎÌõ¼þÏÂת¼³öÀ´µÄËùÓÐmRNA¡£¡£¡£¡£
Ñù±¾ÆðʼÁ¿ÓëËÍÑù½¨Òé
Ñù±¾ÀàÐÍ |
ÆðʼÁ¿ |
ϸ¾ú |
>200 mg |
×ÜRNA |
>1μgÇÒRIN>7.0 |
×¢ÖØÊÂÏ
¢Ù ½¨ÒéÍøÂç¶ÔÊýÉúºã¾ÃµÄÑùÆ·ËÍÑù£»£»£»£»£»£»
¢Ú ½«Ñù±¾·ÅÈëÒºµªÔ¤ÀäµÄÎÞø¹Ü£¬£¬£¬£¬ddH2O»òÃð¾úµÄPBSºó£¬£¬£¬£¬-80¡æÉúÑÄ»ò¸É±ù¼ÄËÍ£»£»£»£»£»£»
¢Û Ô½·¢ÏêϸµÄÑù±¾×¼±¸Ö¸ÄÏ£¬£¬£¬£¬ÇëÁªÏµÔÚÏ߿ͷþ¡£¡£¡£¡£
·Òë×é
¾µäÖÐÐĹæÔòÖ¸³öDNAת¼±¬·¢mRNA£¬£¬£¬£¬¶ømRNAÖ¸µ¼ÂѰ×Öʵĺϳɣ¬£¬£¬£¬ÂѰ×ÖÊÊÇÉúÔËÆø¶¯µÄÖ÷Òª¼ç¸ºÕß¡£¡£¡£¡£È»¶ø¿ÆÑ§¼ÒÃÇ·¢Ã÷ÈËÀà»ùÒò×éÖÐ70%ÒÔÉϵÄDNA¿ÉÒÔת¼±¬·¢RNA¶ø¾ßÓбàÂëÂѰ×ÄÜÁ¦µÄmRNAÖ»Õ¼3%×óÓÒ£¬£¬£¬£¬ËµÃ÷´ó¶¼×ªÂ¼µÄRNA·Ö×Ó¶¼ÊôÓڷDZàÂëRNA£¬£¬£¬£¬¹ØÓÚRNAµÄ·ÒëÖ÷Òª·ÖΪ£º²»·Ò룬£¬£¬£¬²¿·Ö·Ò룬£¬£¬£¬ÖØÐ·Ò룬£¬£¬£¬Ì«¹ý·Òë¡£¡£¡£¡£
Ëæ×ÅNGSµÄÆÕ±éÓ¦Ó㬣¬£¬£¬·Òë×éѧÑо¿Ñ¸ËÙ³ÉΪÏÖ´úÉúÃü¿ÆÑ§µÄÈÈÃÅÖ®Ò»£¬£¬£¬£¬ÆäÖУ¬£¬£¬£¬ºËÌÇÌåÓ¡¼£²âÐòÊÖÒÕÊǸÃÑо¿µÄÀûÆ÷Ö®Ò»£¨Ribo-seq£©£¬£¬£¬£¬¸ÃÊÖÒÕÓÉWeissman¿ÎÌâ×éÓÚ2009Äê½ÒÏþÔÚScienceÔÓÖ¾ÉÏ¡£¡£¡£¡£ÒÔºóÏà¼ÌÓ¦Óõ½Î¢ÉúÎï¡¢½Íĸ¡¢Ð¡Êó¡¢ÈËÀà×éÖ¯¡¢ÓñÃס¢ÄâÄϽ桢°ßÂíÓãµÈ¶à¸öÎïÖÖÑо¿ÉÏ¡£¡£¡£¡£